

October 7, 2009

EEOICPA LIABILITIES as of SEPTEMBER 30, 2009

PURPOSE

Quality Casualty Consulting (QCC) has been retained by the US Department of Labor (DOL) to estimate liabilities of the government to pay claims under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA). The liabilities are as of the end of the latest fiscal year ending 9/30/09.

This evaluation is for both Part B, which became effective July 31, 2001, and Part E which became effective October 29, 2004. The estimation is based as much as possible on actual experience under the program. It includes no estimate of administrative costs.

Although claims are projected to emerge in the future, we consider only those based on employments before 9/30/09, the as of date. There is no liability calculated for exposure to toxic substances after 9/30/09. There is also no estimate of liability that may result from future law or administrative changes. The estimate does not include any loss adjustment expenses.

CONCLUSIONS

We have estimated liabilities under Part B of the EEOICPA as of 9/30/09 to be \$4,208,726,174, discounted by an interest rate of 4.715%. On an undiscounted basis, the liability is \$6,681,514,227. These numbers are shown in Exhibit 1.

At the end of fiscal year 2008, the Part B liabilities were \$4,043,713,292 discounted by an interest rate of 4.770% and \$6,236,610,079 on an undiscounted basis. The estimate of

liabilities has increased since the end of last year primarily due to higher projected number of cancer claims particularly SEC and a slightly lower rate used to discount losses.

Liabilities under part E of the Act are estimated to be \$3,854,836,876 discounted by the rate above, and \$6,077,121,631 on an undiscounted basis.

At the end of 2008, the Part E liabilities were estimated to be \$4,055,605,311 discounted by the rate above, and \$6,829,426,204 on an undiscounted basis. The liabilities have decreased moderately primarily due to payments in 2008 and change in projected decay rate of Part E claims.

The estimate of liability is an actuarial central estimate, an estimate that represents an expected value over the range of reasonably possible outcomes. There are no recoverables for this coverage.

BACKGROUND ON THE EEOICPA

Under Part B, the act provides a lump sum "indemnity" award of \$150,000 and medical benefits to living claimants who were employed in various energy-related activities either directly for the Department of Energy (DOE), or its contractors and sub-contractors. Claimants may include the survivors of deceased workers who would have been eligible for the awards and, in that case, the lump sum is divided among eligible survivors.

Coverage is coordinated with benefits to certain uranium workers under the Radiation Exposure Compensation Act (RECA). Individuals who have received, or will receive, the \$100,000 indemnity benefit under that act are presumed eligible for a \$50,000 indemnity award under the EEOICPA to "top up" the RECA benefit. Liability for benefits has been transferred by the 2004 amendments so that RECA ground-up payments, including medical, have been assumed by the DOL under the EEOICPA.

Except for some broadening of coverage in the coordination with RECA, Part B coverage is for certain specified diseases only: cancer due to radiation exposure, and beryllium disease or silicosis related to exposure to those elements. These must be related to exposures at covered employment and exposures must satisfy certain temporal requirements. Special cases, workers with beryllium sensitivity, qualify for only certain medical benefits.

In a significant expansion of coverage to employees of contractors and subcontractors of the government, Part E was also added to the act, effective October 29, 2004. This extends federal compensation and medical benefits in lieu of state workers compensation benefits for injury and lost income of workers who developed occupational illness as a result of exposure to a broader selection of toxic substances at a DOE facility. This replaced Part D, which provided help to these workers in obtaining state benefits. Old Part D claims have been transferred to the new Part E program. Many claimants already accepted under Part B and RECA will be considered eligible for Part E benefits.

There are detailed requirements, which are only outlined below, that must be fulfilled in order to qualify for benefits under Part B. It should be noted that workers from certain specific locations are in the Special Exposure Cohort (SEC) and have been given favorable status towards acceptance. The SEC is workers at specific locations before February 1, 1992 who worked at least 250 days and have developed certain specific types of cancer.

Claimants must not be suing the government in tort nor be convicted felons. To receive awards, claimants must accept the lump sum payment in full for all claims against the US, DOE and its contractors and sub-contractors. For the purposes of this evaluation, we have assumed that all claimants will accept the EEOICPA award, dropping any lawsuits that may be pending.

THE DATA

Data that has been made available to us are extracts made to our specifications from a database constructed by the program administrators. There are several tables of data, many of which relate to details of the administration of the claims and are not relevant to our estimation. The tables with information useful in the estimation of liabilities contain key information on case (employee) and several with information by claim (which may be either the living employee or one or more of his/her survivors). Extracts requested by us include information on the employee (such as birth date, date of death, and disease), claimant (such as relationship, time of filing and payment), and claim status (relating to eligibility and possible administrative decisions to accept or deny.) We also obtained information on medical condition, claims with SEC status, and payments. These extracts were done as of July 2009. By using our model, we were able to project to an evaluation as of 9/30/09.

In addition to the above extracts, we were able to obtain information on EEOICPA medical payments by case from inception to 7/09 and RECA benefits paid on behalf of DOJ.

We do not have a count of workers by year or location that have been exposed to dangerous substances.

OVERVIEW OF THE ANALYSIS

The general approach to evaluating Part B has been to estimate ultimate case count by medical condition, or disease, and extend that by the dollar value of the indemnity award, \$150,000. The critical injury types in this case are covered cancers, beryllium disease and chronic silicosis. Beryllium sensitivity is subject to medical awards only, and these cases were separated out. RECA cases which originated from a different program were also separated out.

To best use the available experience, we have done the estimate of future compensation respective of disease. We also separated out medical payments, which will have a different payment pattern than compensation.

Using the RECA indicator field, we first separated out cases resulting from coordination with the Radiation Exposure Compensation Act (RECA), which are mostly radiation-induced cancer and other lung diseases. Prior to the October 2004 changes, these were subject to a \$50,000 award per case under EEOICPA. Since it is expected to have a different administration and acceptance rate, RECA is treated as one of the qualifying diseases and these cases are separated out first. As a result of the October 2004 changes, new RECA cases will be paid the full \$150,000 under EEOICPA.

Prior to 2007, the \$100,000 per case paid on behalf of the DOJ on RECA cases was not included in our paid data. For the last several years we have obtained data on payments on behalf of the DOJ for RECA cases from a separate data base and are able to add these amounts to the \$50,000 per case paid by the DOL to obtain the total amount paid. This year, as in the past several years, the projection of liability for RECA cases use \$150,000 per case and thus incorporates both the \$50,000 per case payable under the original Part B and the additional amounts payable on behalf on the DOJ.

We assign cases to medical condition in the following priority order: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer other than SEC and beryllium sensitivity. If more than one condition appeared for any given case, we used that order to slot the case.

Using the data from our extract, we projected the pattern and ultimate number of reported Part B cases by disease using an exponential decay model. Included in this projection is the emergence pattern for cases, that is, the number of cases projected to be filed each quarter for 21 years into the future.

We did not directly model the detailed process by which these diseases are judged to qualify for an award, but, based on sample recommendation and final approval rates, we selected estimates of the approval rate for cases of each disease.

Separate files were provided for Part E claims with dates, status and payment amount, allowing overlap with Part B claims just as awards are allowed to overlap. At this point, dividing Part E cases by disease seems unnecessary. We projected future emergence of cases in much the same way as for Part B cases. We also used information on the payments to date to estimate an average Part E indemnity award. For Part E we projected cases to be filed each quarter for 36 years into the future.

Medical payments are recorded to case and for cases approved under both Part E and Part B, the medical payments cannot be distinguished. We used a similar method to that of the DOL for allocating medical payments to Part B and Part E. Medical is counted as Part E only if there is no Part B claim or if the Part B claim is denied and the Part E claim is approved. Medical data is presented in Exhibit 2.

This year there was a problem with the medical data originally received from DOL. The putative payments in fourth quarter 2007 were extremely high and the payments in second quarter 2009 were very low. We talked to DOL and obtained a new medical data extract as

of September 2009. In comparing the two files, we noticed that amounts in the original file with paid dates of 12/13/2007 and 12/20/2007 now appear as amounts with paid dates in second quarter 2009. The total amount paid from the original file was reasonable compared to statistics on EEOIC on the web site, as well as compared to the new file. Since we only use the totals and a general idea of the trend, we did not revise all the exhibits.

We projected the annual medical benefit paid under Part B to be \$9,540 for 2010, 6% higher than the selected Part B medical benefit for 2009 used last year. For Part E we selected \$3,800. The selected escalation rate is 6%, the same as last year. There is a difference in presentation from last year. Last year both Part B and Part E annual medical benefit were selected the same, \$9,000, but a factor of 40% was applied to Part E medical to account for cases where the Part B claim was approved and medical is paid under Part B. The medical annual payment selected this year for Part E is approximately 40% of the Part B annual payment.

For Part B, we estimated quarterly average medical benefit per living employee with an approved case. This average medical benefit is taken over a broader base of employees and is thus smaller than the average medical amount paid to claimants actually receiving benefits. We calculated averages for Part B in total and for each of the larger disease categories: RECA, cancer SEC and cancer non-SEC. We also calculated an average medical for beryllium disease, chronic silicosis, and beryllium sensitivity combined. The average annual benefit is four times the quarterly.

We also projected the numbers of eligible employee claimants living during each future quarter who could receive ongoing medical benefits. The product of the average medical benefit and the number of eligible employees is the projected medical benefit.

After projecting the number of claims that will be filed and approved, we estimate how long after the claims are filed that they are paid to determine the compensation payment pattern. The number of claims paid times the average benefit is the amount paid.

DETAILED METHODOLOGY

Since the full award inures to the case, not the claim, we consolidated the data to a case basis. We segregated cases by disease using claim data, and we prioritized diseases so that cases coded to multiple diseases could be assigned to one disease.

A. Construction of database

For Parts B and E combined:

From the case (.cas) table, we extracted date of birth, date of death, and sex.

Medical amounts paid by case were provided in a table of medical benefits.

For each Part, B and E separately:

From the claim (.claim) table, we determined the case number, the date filed (earliest claim filed), if the claim was for employee, survivors or both, and if the claim was RECA.

From the medical condition table (.med_condition), we determined the disease using the primary medical condition code. We used a priority order if there was more than one disease listed. The priority was as follows: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer non SEC, beryllium sensitivity, other lung, renal, other, 99 (Other Conditions, Not Listed) and blank. This was used to stratify the cases.

From the claim status table (.claim_status_history), we determined an approval status of each case. We recorded if Final Adjudication Branch (FAB) affirmed or denied an underlying claim, if approval was recommended or denied by the district administrators, or if it were closed. By assumption, approval of one underlying claim inured to the case.

Paid dates and amounts were taken from the payment (.payment) table. From claim payment data we received, we combine amounts paid by claim to case for each full quarter up to the one ending 6/08.

For Part B only:

If a claim is indicated as SEC in the SEC table (.emp_sec) or has an "SE" in the status history table (.claim_status_history), the claim was classified as SEC. If any underlying claim was SEC, then the case was so coded as SEC in our database.

This year, as last year, we have obtained all amounts paid by the DOL on behalf of the DOJ for RECA claims. This is \$100,000 per RECA claim. These amounts are summarized by date paid and added to the \$50,000 per claim paid on RECA claims in the database.

For Part E only:

From the acceptance of payment table, the breakdown of payment by lump sum, wage loss, and impairment was determined.

- B. Estimating an emergence pattern of paid cases, respective of disease
 - 1. Estimate the ultimate number of reported cases and an emergence pattern by disease.

Using this model, we estimate ultimate number of reported cases, as well as a pattern of reporting.

We start with the reported case count as of the latest full evaluation, 6/30/09. Using case counts reported by quarter, we determine a reporting pattern. Using an exponential decay model we determine how many cases are expected to be filed (in a statistical sense) in each of the upcoming quarters. Projections based on the fitted exponential decay model imply few cases will be filed after 2030 for Part B and after 2045 for Part E. We limit the number of years in our case projection exhibits to 21 for Part B and 36 for Part E, not including the 8 completed years. Medical payments are projected out over 50 years. Beyond this time there will undoubtedly be payments, but far fewer and highly discounted for interest. Most of the cases involve workers in their sixties, so these time frames are not unreasonable.

Before fitting the exponential model, some judgment was necessary to adjust quarters with an apparent excess of reported cases, typically the first quarter of the program, which was the third quarter of 2001. There presumably was a backlog of cases brought out by the new program. We excluded this quarter. We also judgmentally adjusted the fitted parameters to be reasonable and consistent with each other across diseases.

2. Estimate the number of reported cases that will be approved and paid. This we have done using approval rate statistics by disease that we derived from the status history table, so that a sample rate of approval is the number of approved cases divided by the total (approved + disapproved). We look at approval rates based on both the divisional recommendations and the Final Adjudication Branch (FAB) but since there is enough history on approval rates, we generally select an approval rate based on the FAB approval rate.

C. Estimating a payment pattern

- 1. We start with the emergence pattern estimated as described in Section B.1 above. We assumed Part B cases other than CN-NONSEC are paid one year after they are reported with a three year lag for CN-NONSEC cases. For Part E we assume a one year lag from filing to approval and two year duration of payments. For some diseases, the payout assumptions lead to a large number of cases to be paid in the year following the estimate. To avoid this lump of cases, we spread the difference uniformly between the estimated approved cases and the number paid to date over five years for RECA, CN-SEC, BD, and CN-NONSEC cases. For Part E the correction term is spread over 10 years.
- 2. Compensation payment amounts are \$150,000 for part B cases. (RECA payments, which were once only \$50,000, are now also projected at \$150,000). For Part E, we estimated an average award of \$143,000 using analysis described in Exhibit 3, page 5.

- 3. Medical payment amounts are derived by estimating an average benefit award per eligible employee and a projection of how many such employee claimants are living in each year after the current. We selected \$9,540 for Part B and \$3,800 for Part E as the average amount paid in 2010. The Part B selection is higher than the current indication for Part B but we expect a higher percentage of future claims to be CN-SEC which has higher than average medical costs. For projecting future medical payments, we retained our estimate of medical inflation at 6%.
- 4. To project living employee claimants, those eligible for medical benefits, we used mortality rates for existing disabled male retirees from the RP-2000 Mortality Tables published by the Society of Actuaries, as well as our model estimate of new claimants emerging.

DESCRIPTION OF EXHIBITS

Exhibit 1, page 1 - The Estimate of EEOICPA Liabilities.

Usually liability is computed as the ultimate incurred minus paid loss to date, where loss is compensation plus medical. In this case, we used our model of the payment stream by disease and directly summed payments starting 10/01/09. We also calculate discounted liabilities using our payment pattern from Exhibit 6 and an interest rate of 4.715%.

Exhibit 1, page 2- Assumptions used in the calculations

The assumptions are for discount rate, approval rate, portion of cases filed by living employee, mortality rates, medical cost and inflation rates.

Exhibit 2 - Summary Medical Paid Loss Data

Averages are taken over several different disease groups.

Exhibit 3 - Summarized Information from our Data Base

Tables 1 through 12 show summarized information from the database.

From this data, we estimated a case approval rate and payments made by disease and year. The approval of a case required only that one underlying claim be approved, and we did not count a case as disapproved if any underlying claim was approved or reopened.

Exhibit 3, page 5 – Estimate of Part E average compensation award

The various possible types of cases and claimants are weighted to produce a single average award. Because of possible overlap in the categories, the weights used in the selection total to more than 100%.

Exhibit 4 - Estimation of Ultimate Case Count and Emergence Pattern by Disease

To calculate the ultimate number of cases reported by disease, we projected based on reported case counts from the latest 31 quarters in our database. This excluded the third quarter of 2001. We fit an exponential decay reporting pattern to the quarterly data. Using actual cases as of 6/30/09, the last complete quarter, and the fitted pattern for projection, we were able to calculate an expected ultimate number of reported cases. We selected exponential parameters that may have differed from the values resulting from the fit on the existing data usually by comparing last years projections for the current year to the actual number of claims filed and by comparing future projection with the latest reported numbers.

In addition to an estimate of an ultimate number of cases, the exponential decay model also gives us a reporting pattern, which we have used to derive a payment pattern for discounting.

Exhibit 5, page 1 - Estimated Ultimate Approved Cases by Disease

Using the selected approval rate by disease from Exhibit 1 and the number of filed claims from Exhibit 4, we calculated the expected number of cases reported by fiscal year that would be approved.

Exhibit 5, page 2 - Estimated Ultimate Paid Cases by Disease

The database gives us information about the difference between the filing date and the approval date. For all Part B diseases except CN-NONSEC, we assumed payout would follow the year after the (approved) case was filed. For CN-NONSEC we assumed payout three years after filing. Part E cases are assumed to be paid 3 years after filing which represents 1 year from filing to approval and a two year duration of payments. This assumes that cases will be decided more quickly now that most of the initial backlog of claims has been handled. Further adjustments are made as described in the exhibit and in section C1 of this report.

Exhibit 5, page 3 – Cases Eligible for Medical Expenses

To be eligible for medical, claims must be approved and filed by a living employee. Once he/she becomes eligible, the claimant continues to be eligible in subsequent years, subject to mortality.

Exhibit 6 - Dollars Paid by Disease by Fiscal Year

The liability by disease is the sum of projected payments after 9/30/09, and summarized on Exhibit 1.

The projected payout of cases is used in conjunction with actual payments to date to derive the payout distribution by fiscal year, which can be used with a selected interest rate to discount the liabilities. The interest rates decreased a little this year compared to last year so the discounted liabilities are somewhat higher than if last years interest rate was used.

Exhibit 7 – Sensitivity Analysis

By far the most sensitive part of our analysis is the projection of ultimate emerged cases. This is especially difficult because we don't really know the true exposure to loss, which is the number of at-risk employees. Though there have been some estimates in total and maybe by occupation, what we would really like is number of employees by year of employment. As far as we know, this is not available.

Our other selections have less overall impact, but correlation of these is possible and the consequent error in our projection of these could still be quite large. Exhibit 7 shows estimates of liability with some different parameter selections to provide an idea of how much the estimate could vary if different parameters were selected.

- 1. An exponential decay model is reasonable if there are no exogenous factors, but with existing changes in administration such as awareness programs and the addition of new SEC classes, we see actual changes that cannot fully be modeled. For sensitivity, we tested the impact of increasing and decreasing the selected slope parameter one percentage point, 0.01. This sounds like a small change but the slope parameters are in the range .02 to .09 so .01 is a large percentage change. The increase in slope increased discounted reserves some 47%, while the decrease reduced them 24%. The model is especially sensitive to this selection.
- 2. The choice of Medical inflation rate can also have great impact. Our selection of 6% is higher than that selected by the Office of Management and Budget (OMB) for projecting FECA medical payments in the DOL model, but is certainly reasonable. Our tests show the impact of varying this assumption is that an 8% rate would increase discounted total reserve 10.5% and a 4% rate would reduce discounted total reserves 7.5%.
- 3. Change in Medical cost per case has a lesser impact on reserves so that a 10% increase in the cost per case increases total reserves only 3.8% while a 10% decrease in that cost reduces reserves by the same percentage. Our choice of medical average cost has moderate impact.
- 4. Approval rates have a slightly leveraged impact, so that a 10% higher approval rate increases the reserve over 16% while a 10% lower approval rate tends to reduce reserves 17%. The approval rates have become more stable for all diseases except possibly Part E. Re-adjudication of previously denied claims has increased the uncertainty of the long term approval rate.
- 5. Interest rates can have great impact. We used the OMB's recommendations for long term interest rates used in the FECA reserves and see little need for judgmental

adjustment. We show a one point change in interest rate can impact reserves about 7-9%.

CHANGES IN METHODOLOGY

The major changes in methodology compared to last years analysis:

- 1) Rather than a factor applied to Part E medical we selected distinct medical costs per case for Part E and Part B. This is actually a presentation change rather than a methodology change.
- 2) We adjusted the assumptions as to how long it takes to pay a claim. CN-NONSEC cases are assumed to be paid three years after filing instead of two. BD, CS are assumed to be paid one year after filing instead of two. Part E claims are assumed to be paid 3 years after filing instead of 4. These changes were made because it appears generally that most claims are being paid faster now that the backlog is clearing. Claims that go to NIOSH still require a significant time to settle, which may explain why CN-NONSEC claims take longer to settle..
- 3) The selected approval rates and decay rates for some diseases are changed based on the new data. Of most significance, Part E approval rate is increased from 40% to 44%, the decay rates for cancer claims, CN-SEC and CN-NONSEC are decreased and the decay rate for Part E is increased.

CAVEATS

This work is a good faith estimate of the EEOICPA liabilities. We have tried to use the actual experience as much as possible to make our estimate and also give weight to information from staff about changes in the program that are not yet seen in the data. Nevertheless, the estimate is based to a great extent on judgment. As with all such estimations of future contingent events, this one, even based on known experience, includes a significant probability of being incorrect. This risk is contained in all actuarial estimations of future costs, but is particularly high in this case.

The EEOICPA program is relatively new, with only a short history to serve as an example of possible events especially when compared to a commercial line of insurance such as Workers Compensation or Premises Liability. The EEOICPA experience so far is only a fraction of the ultimate events that will occur as this program plays out. Part E in particular has generated very little experience so we are relying heavily on judgment to produce estimates.

We relied on the data supplied by the Department of Labor to make this estimate. We examined it for consistency and reasonableness but otherwise relied on the accuracy of the information provided to us.

What actuaries call the exposure to loss - the time, place, people and what they were doing many years ago - is not measured very accurately in comparison to commercial insurance lines of business, where we would have audited payroll by year and location, and comparatively prompt notification of insured events. In this case, eligible claimants were working at several different locations during many different time periods spanning many years in the past.

Qualification for the benefits is based on a newly instituted and evolving administrative procedure, again with not much historical experience to model the process. One constant has been that for Part B, the size of the awards: a flat lump sum of \$150,000. This helps reduce possible error in the estimate. For Part E there are varying possible awards adding another source of error in the estimate.

There are three possible kinds of risk in all estimations. One is parameter risk, or the risk that our model of the process is not accurate. There are many variables that impact the results and it is possible that some of them are not estimated accurately. The parameter risk in this case is sizable.

Another is called process risk. Even if we are able to correctly model the loss process, it is, after all, stochastic, and actual events may depart from what we predict, even if what we predict is correct on average. Actuaries would call this average the true expected losses. Because the possible triggers for an award under the EEOICPA are so complex, process risk is high, and fortuitous events in the future may not follow patterns seen in the data.

The third is model risk. This is the risk that the model is not appropriate for the estimate. For example, the exponential decay model for modeling the number of claims may not be appropriate for this particular coverage.

Judy A. Gillam, FCAS, MAAA

John a. Killam

William R. Gillam, FCAS, MAAA

William R Gillam

ESTIMATED LIABILITY FOR EEOIC AS OF 9/30/2009

Part B Part E Total Undiscounted Future Liability \$6,681,514,227 \$6,077,121,631 \$12,758,635,858 Discounted Liability \$4,208,726,174 \$3,854,836,876 \$8,063,563,050 Using an interest rate of 4.715%

ESTIMATED PAYOUT FOR CURRENT EEOIC LIABILITY

ESTIMATED PATOUT FOR CORNENT EEOIC LIABILITY						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
				$= (3) \times (4)$		$=(3) \times (6)$
			PART B	PART B	PART E	PART E
	Years of			Discounted	Undiscounted	
Fiscal Year	Discount	Discount Factor	Undiscounted Payout	Payout	Payout	Discounted Payout
10/09-9/10	0.5	0.977	469,671,900	458,869,446	486,442,600	475,254,420
10/10-9/11	1.5	0.933	420,508,704	392,334,621	412,464,836	384,829,692
10/11-9/12	2.5	0.891	405,038,517	360,889,319	385,842,310	343,785,498
10/12-9/13	3.5	0.851	385,650,856	328,188,878	357,863,820	304,542,111
10/13-9/14	4.5	0.813	368,597,060	299,669,410	332,365,579	270,213,216
10/14-9/15	5.5	0.776	301,823,596	234,215,110	310,228,565	240,737,366
10/15-9/16	6.5	0.741	286,343,838	212,180,784	290,852,870	215,521,977
10/16-9/17	7.5	0.708	272,512,090	192,938,560	273,536,012	193,663,496
10/17-9/18	8.5	0.676	260,704,165	176,236,016	258,701,774	174,882,399
10/18-9/19	9.5	0.646	249,734,424	161,328,438	245,036,720	158,293,721
10/19-9/20	10.5	0.616	239,064,000	147,263,424	188,500,025	116,116,015
10/20-9/21	11.5	0.589	228,150,100	134,380,409	176,859,402	104,170,188
10/21-9/22	12.5	0.562	218,369,144	122,723,459	165,755,640	93,154,670
10/22-9/23	13.5	0.537	209,037,812	112,253,305	155,807,340	83,668,542
10/23-9/24	14.5	0.513	199,823,963	102,509,693	146,445,387	75,126,484
10/24-9/25	15.5	0.490	191,570,535	93,869,562	137,846,972	67,545,016
10/25-9/26	16.5	0.468	183,033,565	85,659,708	129,727,696	60,712,562
10/26-9/27	17.5	0.447	174,515,670	78,008,504	121,999,009	54,533,557
10/27-9/28	18.5	0.426	166,085,230	70,752,308	114,824,996	48,915,448
After 9/28			1,451,279,058	444,455,220	1,386,020,078	389,170,498
TOTAL			\$6,681,514,227	\$4,208,726,174	\$6,077,121,631	\$3,854,836,876

Column (4) payout is from Exhibit 6 column (9) excluding amounts paid before 9/30/09

Column (6) payout is from Exhibit 6 column (12) excluding amounts paid before 9/30/09

Column (3) is 1 divided by 1 plus the interest rate selected for discounting, raised to the power in column (2)

13 10/7/2009

Inputs for Estimation of EEOIC liabilities

Exhibit 1 Table 1 Page 2

Interest Rate to use for Discounting Reserves 4.715%

Table 2

Selected rate of approval of filed claims Actual data is in Exhibit 3 Page 2 Tables 5 and 6.

95% 53% 18% RECA BD CS CN - SEC 77% CN - NONSEC BS 57% PART E 44%

Table 3

Selected percentage of Cases Filed by Living Employee. These cases are eligible for medical benefits.

Actual data is in Exhibit 3 Page 1 Table 2.

RECA 54% BD 58% CS 72% CN - SEC CN - NONSEC 48% 56% BS 99% PART E

Table 4

Mortality Rates Assumed Average Age at Filing Claim is 67

(1)	(2)) (3)
		= 1-(2)
	Nortality Rate	
67	0.054450	0.9456
68	0.056909	0.9431
69	0.059613	0.9404
70	0.062583	0.9374
71	0.065841	0.9342
72	0.069405	0.9306
73	0.073292	0.9267
74	0.077512	0.9225
75	0.082067	0.9179
76	0.086951	0.9130
77	0.092149	0.9079
78	0.097640	0.9024
79	0.103392	0.8966
80	0.109372	0.8906
81	0.115544	0.8845
82	0.121877	0.8781
83	0.128343	0.8717
84	0.134923	0.8651
85	0.141603	0.8584
86	0.148374	0.8516
87	0.155235	0.8448
88	0.162186	0.8378
89	0.169233	0.8308
90	0.183408	0.8166
91	0.199769	0.8002
92	0.216605	0.7834
93	0.233662	0.7663
94	0.250693	0.7493
95	0.267491	0.7325
96	0.283905	0.7161
97	0.299852	0.7001
98	0.315296	0.6847
99	0.330207	0.6698
100	0.344556	0.6554
101	0.358628	0.6414
102	0.371685	0.6283

Column (2) Mortality Rates are from Male RP-2000 Rates for Disabled Retiree

Table 5

Selected Part B Medical Annual Cost		\$9,540
Selected Part E Medical Annual Cost		\$3,800
Medical Inflation Rate =	6%	

(1) Fiscal Year Ending	(2)	(3) Avg. Medical Benefit	
		Part B	Part E
9/10	1	9,540	\$3,800
9/11	2	10,112	4,028
9/12	3	10,712	4,270
9/13	4	11,362	4,526
9/14	5	12,044	4,797
9/15	6	12,767	5,085
9/16	7	13,533	5,390
9/17	8	14,345	5,714
9/18	9	15,205	6,057
9/19	10	16,118	6,420
9/20	11	17,085	6,805
9/21	12	18,110	7,214
3/21	12	10,110	7,214

Column (3) is the medical annual cost times 1 plus the medical inflation rate raised to the power in column (2) - 1 Actual data from Exhibit 2 Table 1.

> 14 10/7/2009

Exhibit 2 Page 1

Table 1

ALL PARTS B AND E

Actual Medical Paid Quarterly Per all Eligible Cases (3) (4) (1) (2) = (4) / (3)Total Cases Eligible Cumulative Medical Paid Average 3Q 2001 -1,359,487 -27.190 50 50 4Q 2001 404 454 2,153 1Q 2002 374 828 302,794 366 2Q 2002 383 1,211 1,537,000 1,269 3Q 2002 1,980,454 1,224 407 1,618 4Q 2002 457 2,075 1,743,499 840 1Q 2003 388 2,463 3,437,996 1,396 2Q 2003 4,334,275 2,707 1,601 244 3Q 2003 177 2,884 5,223,288 1,811 4Q 2003 208 3,092 4,178,941 1.352 1Q 2004 3,338 246 7,171,777 2,149 2Q 2004 216 3,554 6,443,989 1,813 3Q 2004 222 3.776 5.207.840 1.379 4Q 2004 3,987 6,833,070 1,714 211 1Q 2005 249 4,236 7,931,955 1,873 2Q 2005 4,542 1,996 306 9,065,376 3Q 2005 4,859 1,841 317 8,947,440 4Q 2005 303 5,162 7,855,636 1,522 1Q 2006 374 5,536 11,330,589 2,047 2Q 2006 415 5,951 12,171,679 2,045 3Q 2006 486 6,437 10,275,928 1,596 4Q 2006 461 6,898 9,403,769 1,363 1Q 2007 624 7.522 13,410,427 1.783 2Q 2007 930 8,452 17,336,369 2,051 3Q 2007 1,092 9,544 20,345,258 2,132 4Q 2007 10,525 32,426,159 981 3,081 1Q 2008 887 11,412 17,806,320 1,560 2Q 2008 1,061 12,473 19,529,486 1,566 1,222 3Q 2008 13,695 23,313,996 1,702 4Q 2008 1,178 14,873 26,900,012 1,809 1Q 2009 15,852 26,209,149 1,653 979 1,083 2Q 2009 16,935 15,181,449 896 16,935 196,941 336,478,585 1,709

There is a problem with the medical data by quarter, namely that amounts with paid dates of 12/13/2007 and 12/20/2007 should show paid dates in second quarter 2009. This was determined from a new file of medical data provided by DOL. Since the totals are correct and our selections of medical quarterly payments are not affected, the exhibits were not revised for the new data.

ESTIMATE OF PAID MEDICAL FOR EEOIC					
ALL PART B					Exhibit 2
Actual Medical Paid Q	uarterly Per all Eligible C	Cases			Page 2
(1)	(2)	(3)	(4)	(5)	_
			Total	= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
3Q 2001	50	50	-1,289,764	-25,795	
4Q 2001	404	454	2,153	5	
1Q 2002	374	828	302,794	366	
2Q 2002	383	1,211	1,537,000	1,269	
3Q 2002	407	1,618	1,980,379	1,224	
4Q 2002	457	2,075	1,743,108	840	
1Q 2003	388	2,463	3,431,229	1,393	
2Q 2003	244	2,707	4,326,868	1,598	
3Q 2003	177	2,884	5,214,066	1,808	
4Q 2003	208	3,092	4,171,814	1,349	
1Q 2004	246	3,338	7,160,515	2,145	
2Q 2004	216	3,554	6,424,221	1,808	
3Q 2004	222	3,776	5,185,806	1,373	
4Q 2004	211	3,987	6,824,268	1,712	
1Q 2005	249	4,236	7,911,125	1,868	
2Q 2005	306	4,542	9,022,578	1,986	
3Q 2005	315	4,857	8,842,301	1,821	
4Q 2005	296	5,153	7,691,419	1,493	
1Q 2006	359	5,512	10,647,940	1,932	
2Q 2006	380	5,892	11,513,923	1,954	
3Q 2006	422	6,314	9,461,669	1,499	
4Q 2006	352	6,666	8,482,169	1,272	
1Q 2007	422	7,088	12,158,684	1,715	
2Q 2007	540	7,628	15,994,352	2,097	
3Q 2007	512	8,140	18,757,561	2,304	
4Q 2007	409	8,549	28,711,931	3,359	
1Q 2008	389	8,938	16,165,690	1,809	
2Q 2008	337	9,275	17,599,490	1,898	
3Q 2008	441	9,716	19,826,304	2,041	
4Q 2008	421	10,137	23,035,395	2,272	
1Q 2009	296	10,433	22,236,790	2,131	
2Q 2009	300	10,733	12,129,715	1,130	
-		4000	007.000 :	4.050	
Total	10,733	165,846	307,203,490	1,852	

16 10/7/2009

ESTIMATE OF PAID MEDICAL FOR EEOIC					
PART B RECA					Exhibit 2
Actual Medical Paid Qu	arterly Per all Eligible C				Page 3
(1)	(2)	(3)	(4)	(5)	
			Total	= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
3Q 2001	37	37	-230,230	-6,222	
4Q 2001	290	327	800	2	
1Q 2002	108	435	82,905	191	
2Q 2002	82	517	85,981	166	
3Q 2002	109	626	186,475	298	
4Q 2002	100	726	201,816	278	
1Q 2003	82	808	391,191	484	
2Q 2003	50	858	729,448	850	
3Q 2003	41	899	1,092,352	1,215	
4Q 2003	62	961	937,513	976	
1Q 2004	79	1,040	1,249,458	1,201	
2Q 2004	83	1,123	1,256,372	1,119	
3Q 2004	79	1,202	1,250,506	1,040	
4Q 2004	51	1,253	2,798,399	2,233	
1Q 2005	110	1,363	3,918,187	2,875	
2Q 2005	122	1,485	4,207,671	2,833	
3Q 2005	97	1,582	3,691,239	2,333	
4Q 2005	81	1,663	2,420,970	1,456	
1Q 2006	92	1,755	5,134,562	2,926	
2Q 2006	65	1,820	4,997,519	2,746	
3Q 2006	105	1,925	3,692,906	1,918	
4Q 2006	78	2,003	3,067,159	1,531	
1Q 2007	155	2,158	4,547,307	2,107	
2Q 2007	257	2,415	6,701,169	2,775	
3Q 2007	237	2,652	6,630,057	2,500	
4Q 2007	142	2,794	10,457,107	3,743	
1Q 2008	112	2,906	5,825,866	2,005	
2Q 2008	67	2,973	6,492,837	2,184	
3Q 2008	102	3,075	6,734,903	2,190	
4Q 2008	80	3,155	8,750,907	2,774	
1Q 2009	74	3,229	8,081,153	2,503	
2Q 2009	52	3,281	3,808,843	1,161	
Total	3,281	53,046	109,193,350	2,058	

ESTIMATE OF PAID MEDICAL FOR EEOIC					
PART B CN-SEC					Exhibit 2
Actual Medical Paid Quart	erly Per all Eligible C				Page 4
(1)	(2)	(3)	(4)	(5)	
			Total	= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
3Q 2001	13	13	-553,902	-42,608	
4Q 2001	83	96	1,354	14	
1Q 2002	177	273	217,818	798	
2Q 2002	115	388	1,415,875	3,649	
3Q 2002	131	519	1,644,930	3,169	
4Q 2002	103	622	1,272,103	2,045	
1Q 2003	100	722	2,020,038	2,798	
2Q 2003	86	808	2,288,713	2,833	
3Q 2003	44	852	3,084,031	3,620	
4Q 2003	53	905	2,531,516	2,797	
1Q 2004	52	957	4,486,358	4,688	
2Q 2004	44	1,001	3,997,496	3,994	
3Q 2004	50	1,051	2,975,627	2,831	
4Q 2004	57	1,108	2,892,098	2,610	
1Q 2005	38	1,146	3,038,001	2,651	
2Q 2005	55	1,201	3,310,522	2,756	
3Q 2005	77	1,278	3,379,561	2,644	
4Q 2005	103	1,381	3,595,667	2,604	
1Q 2006	101	1,482	3,895,692	2,629	
2Q 2006	108	1,590	3,980,363	2,503	
3Q 2006	113	1,703	3,606,309	2,118	
4Q 2006	88	1,791	3,358,779	1,875	
1Q 2007	93	1,884	4,846,738	2,573	
2Q 2007	95	1,979	6,159,044	3,112	
3Q 2007	126	2,105	8,114,108	3,855	
4Q 2007	155	2,260	12,381,504	5,479	
1Q 2008	147	2,407	6,684,999	2,777	
2Q 2008	132	2,539	6,888,016	2,713	
3Q 2008	194	2,733	8,045,711	2,944	
4Q 2008	211	2,944	9,470,257	3,217	
1Q 2009	129	3,073	8,419,718	2,740	
2Q 2009	144	3,217	4,852,298	1,508	
Total	3,217	46,028	132,301,341	2,874	

PART B CN-NONSEC					Exhibit 2
Actual Medical Paid Or	arterly Per all Eligible C	2266			Page 5
(1)	(2)	(3)	(4)	(5)	r ago o
(.,	(=)	(0)		= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
3Q 2001	0	0	-101,910	9	
4Q 2001	0	0	0		
1Q 2002	0	0	0		
2Q 2002	0	0	0		
3Q 2002	0	0	1,297		
4Q 2002	2	2	3,694	1,847	
1Q 2003	0	2	29,431	14,715	
2Q 2003	8	10	21,720	2,172	
3Q 2003	13	23	35,344	1,537	
4Q 2003	41	64	51,597	806	
1Q 2004	37	101	169,658	1,680	
2Q 2004	29	130	125,188	963	
3Q 2004	33	163	210,135	1,289	
4Q 2004	61	224	273,744	1,222	
1Q 2005	57	281	273,938	975	
2Q 2005	79	360	443,974	1,233	
3Q 2005	103	463	581,264	1,255	
4Q 2005	78	541	598,923	1,107	
1Q 2006	130	671	654,864	976	
2Q 2006	153	824	1,485,979	1,803	
3Q 2006	158	982	975,085	993	
4Q 2006	140	1,122	999,405	891	
1Q 2007	116	1,238	1,624,787	1,312	
2Q 2007	122	1,360	1,874,649	1,378	
3Q 2007	72	1,432	2,495,018	1,742	
4Q 2007	47	1,479	3,406,657	2,303	
1Q 2008	69	1,548	1,865,574	1,205	
2Q 2008	76	1,624	2,089,742	1,287	
3Q 2008	84	1,708	3,346,606	1,959	
4Q 2008	63	1,771	3,091,971	1,746	
1Q 2009	50	1,821	3,352,695	1,841	
2Q 2009	59	1,880	2,190,744	1,165	
Total	1,880	21,824	32,171,774	1,474	

19 10/7/2009

PART B BD, CS, AND BS
Actual Medical Paid Quarterly Per all Eligible Cases

Actual Medical Paid Qu		ases			Page 6
(1)	(2)	(3)	(4)	(5)	i ago o
(.)	(-)	(0)	Total	= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
3Q 2001	0	0	-403,723		
4Q 2001	31	31	0	0	
1Q 2002	89	120	2,070	17	
2Q 2002	186	306	35,144	115	
3Q 2002	167	473	147,678	312	
4Q 2002	252	725	265,495	366	
1Q 2003	206	931	990,209	1,064	
2Q 2003	100	1,031	1,286,237	1,248	
3Q 2003	79	1,110	1,001,889	903	
4Q 2003	52	1,162	651,187	560	
1Q 2004	78	1,240	1,255,041	1,012	
2Q 2004	60	1,300	1,044,566	804	
3Q 2004	60	1,360	748,909	551	
4Q 2004	42	1,402	859,826	613	
1Q 2005	44	1,446	680,998	471	
2Q 2005	50	1,496	1,059,840	708	
3Q 2005	38	1,534	1,189,837	776	
4Q 2005	34	1,568	1,075,859	686	
1Q 2006	36	1,604	962,426	600	
2Q 2006	54	1,658	1,048,243	632	
3Q 2006	46	1,704	1,186,027	696	
4Q 2006	46	1,750	1,053,225	602	
1Q 2007	58	1,808	1,133,453	627	
2Q 2007	66	1,874	1,249,706	667	
3Q 2007	77	1,951	1,508,116	773	
4Q 2007	65	2,016	2,437,041	1,209	
1Q 2008	61	2,077	1,782,219	858	
2Q 2008	62	2,139	2,117,516	990	
3Q 2008	61	2,200	1,683,873	765	
4Q 2008	67	2,267	1,698,672	749	
1Q 2009	43	2,310	2,367,054	1,025	
2Q 2009	45	2,355	1,266,887	538	
Total	2,355	44,948	33,385,518	743	

20 10/7/2009

Exhibit 2

ESTIMATE OF PAID MEDICAL FOR ELOIC					
PART E					Exhibit 2
Actual Medical Paid Qua	arterly Per all Eligible C	ases			Page 7
(1)	(2)	(3)	(4)	(5)	
			Total	= (4) / (3)	
	Cases Eligible	Cumulative	Medical Paid	Average	
2Q 2005 & Prior	0	0	86,762		
3Q 2005	2	2	105,139	52,569	
4Q 2005	7	9	164,217	18,246	
1Q 2006	15	24	682,649	28,444	
2Q 2006	35	59	657,755	11,148	
3Q 2006	64	123	814,259	6,620	
4Q 2006	109	232	921,600	3,972	
1Q 2007	202	434	1,251,742	2,884	
2Q 2007	390	824	1,342,017	1,629	
3Q 2007	580	1,404	1,587,697	1,131	
4Q 2007	572	1,976	3,714,228	1,880	
1Q 2008	498	2,474	1,640,630	663	
2Q 2008	724	3,198	1,929,996	604	
3Q 2008	781	3,979	3,487,692	877	
4Q 2008	757	4,736	3,864,617	816	
1Q 2009	683	5,419	3,972,359	733	
2Q 2009	783	6,202	3,051,734	492	
Total	6,202	31,095	29,275,095	941	

Column (2) is from Exhibit 3 Page 3 Table 10
Column (3) is the cumulative sum of column (2)
Column (4) is the total medical from Exhibit 3 Table 11
Eligible cases for medical are all cases with a living employee whether they have received medical benefits or not.

Selected Medical Benefit

PART B	
Selected Quarterly Payment	\$2,385
Selected Annual Payment	\$9,540
PART E	
Selected Quarterly Payment	\$950
Selected Annual Payment	\$3.800
Selected Amiliaan raymem	ψ5,000

Part B selection is based on RECA, CN-SEC, and CN-NONSEC

Table 1

	Number of Cases and Claims By Disease		
	# Cases	# Claims	
RECA	7,010	11,292	
BD	4,123	6,257	
CS	548	763	
CN-SEC	17,540	30,623	
CN-NONSEC	26,226	37,802	
BS	2,198	2,215	
OL	3,060	3,539	
RN	463	571	
OTHER	4,440	4,904	
99	1,327	1,420	
PA	1	1	
Unknown	307	330	
PART B SUBTOTAL	67,243	99,717	
PART E - WITH PART B CLAIM	51,562	74,579	
PART E - ONLY	6,520	7,258	
PART E SUBTOTAL	58,082	81,837	
Cases with no Claims	401	0	
TOTAL	125,726 *	181,554	

 $^{^{\}star}\text{Total}$ number of cases includes cases double counted as Part B and Part E. The total number of cases is 74,164.

Table 2

Cases Filed by Employee or Survivors or Both.										
	(1) (2) (3)									
				Percentage						
	EMP	SUR	BOTH	EMP						
RECA	3,608	3,203	199	54.3%						
BD	2,142	1,724	257	58.2%						
CS	354	154	40	71.9%						
CN-SEC	6,601	9,209	1,730	47.5%						
CN-NONSEC	12,591	11,673	1,962	55.5%						
BS	2,164	28	6	98.7%						
PART E	31,381	23,302	3,399	59.9%						
TOTAL	58,841	49,293	7,593	57.4%						

Column (4) is the sum of Columns (1) and (3) divided by sum of columns (1), (2) and (3).

Table 3 Avg. Age of Employee At Time Claim is Filed

Employee Filed Cases (Only				
	-		Number		Number
Year of Claim Filing		Part B	Cases	Part E	Cases
	2001	67	8,793	65	2,555
	2002	65	7,873	65	5,229
	2003	65	4,890	64	4,630
	2004	67	3,946	67	3,335
	2005	67	3,428	68	5,903
	2006	67	2,831	67	4,006
	2007	68	3,163	67	4,003
	2008	68	2,545	67	3,283
	2009 *	68	1,350	66	1,832
Total		67	38,819	66	34,776

^{* 2009} data is for a partial year

Table 4

Sex of Employee

				Male
	Male	Female	Blank	Percentage
RECA	6,880	116	14	98.3%
BD	3,661	461	1	88.8%
CS	527	20	1	96.3%
CN-SEC	15,232	2,291	17	86.9%
CN-NONSEC	23,158	3,044	24	88.4%
BS	1,764	433	1	80.3%
PART E	50,586	7,152	344	87.6%
Total	101,808	13,517	402	88.3%

22 10/7/2009 Table 5 Table 6

ı	Percentage of Cas	es Recommer	Percentage	of Cases FA	AB Accept	
	Recommend	Recommend	Percentage	FAB		Percent FAB
	Accept	Deny	Rec Accept	Accept	FAB Deny	Accept
RECA	6,411	402	94.1%	6,378	365	94.6%
BD	1,915	2,012	48.8%	2,079	1,829	53.2%
CS	78	431	15.3%	93	410	18.5%
CN-SEC	10,683	4,337	71.1%	11,094	3,590	75.6%
CN-NONSEC	5,262	16,251	24.5%	5,337	15,457	25.7%
BS	1,191	948	55.7%	1,201	915	56.8%
OL	1	2,976	0.0%	1	2,951	0.0%
RN	1	454	0.2%	1	446	0.2%
OTHER	0	4,353	0.0%	0	4,330	0.0%
99	2	1,304	0.2%	2	1,283	0.2%
Unknown	0	141	0.0%	0	140	0.0%
PA	0	1	0.0%	0	1	
SUBTOTAL EXCL F	25,544	33,610	43.2%	26,186	31,717	45.2%
PART E	19,069	30,396	38.6%	21,159	27,148	43.8%
TOTAL	44,613	64,006	41.1%	47,345	58,865	44.6%

Table 7

Report Qtr	Actual Cases Filed B	y Report Qua	arter											
												PART B		
	RECA	BD	CS	CN-SEC C		BS	OL	RN	OTHER	99	Blank	Subtotal	PART E_	TOTAL
No Date	2	0	0	1	8	0	0	0	3	0	2	16	5	21
3Q 2001	1,534	825	123	2,363	3,545	188	534	93	666	164	52	10,087	2176	12,263
4Q 2001	348	353	75	1,055	2,848	112	444	77	502	140	47	6,001	2058	8,059
1Q 2002	284	341	43	1,123	2,274	143	356	60	481	149	36	5,290	2823	8,113
2Q 2002	251	253	20	803	1,386	185	252	40	403	101	46	3,740	2413	6,153
3Q 2002	201	140	17	714	995	152	186	34	262	91	37	2,829	2058	4,887
4Q 2002	154	168	17	488	783	90	133	26	198	48	12	2,117	1714	3,831
1Q 2003	106	130	6	530	833	83	134	21	205	44	0	2,092	1604	3,696
2Q 2003	134	125	11	473	836	90	153	17	323	116	2	2,280	2160	4,440
3Q 2003	120	147	13	417	762	71	74	10	134	39	1	1,788	2045	3,833
4Q 2003	155	153	9	433	774	51	66	10	130	40	0	1,821	1826	3,647
1Q 2004	199	198	14	552	865	48	50	7	130	40	1	2,104	1843	3,947
2Q 2004	121	165	7	437	670	44	36	5	85	25	0	1,595	1142	2,737
3Q 2004	139	207	21	524	754	115	47	7	115	22	0	1,951	1336	3,287
4Q 2004	155	89	14	373	505	30	52	5	93	28	0	1,344	1747	3,091
1Q 2005	211	126	14	418	698	56	75	4	80	46	2	1,730	2910	4,640
2Q 2005	273	98	13	437	671	53	53	6	54	17	2	1,677	3685	5,362
3Q 2005	220	79	9	334	593	44	20	2	64	18	2	1,385	2278	3,663
4Q 2005	167	36	8	368	435	27	16	2	25	6	2	1,092	1795	2,887
1Q 2006	185	42	10	355	459	25	17	1	21	6	1	1,122	1710	2,832
2Q 2006	143	34	5	347	408	45	20	1	23	8	5	1,039	1480	2,519
3Q 2006	310	41	8	320	444	44	23	1	23	9	0	1,223	1588	2,811
4Q 2006	222	42	17	358	423	69	33	0	40	19	5	1,228	1639	2,867
1Q 2007	228	49	9	426	703	67	44	2	65	22	0	1,615	2060	3,675
2Q 2007	177	44	7	360	446	42	14	3	32	14	2	1,141	1426	2,567
3Q 2007	123	55	9	389	478	63	11	1	27	11	3	1,170	1429	2,599
4Q 2007	152	40	14	400	458	39	52	4	81	25	1	1,266	1339	2,605
1Q 2008	150	27	6	388	331	41	33	6	41	18	3	1,044	1206	2,250
2Q 2008	136	27	6	495	319	40	32	4	25	17	1	1,102	1363	2,465
3Q 2008	115	24	10	549	378	35	27	2	25	10	2	1,177	1372	2,549
4Q 2008	95	24	5	412	301	24	24	4	24	9	1	923	1153	2,076
1Q 2009	80	27	4	477	436	38	28	4	41	10	1	1,146	1368	2,514
2Q 2009	95	12	3	369	347	35	19	4	19	15	4	922	1106	2,028
3Q 2009	25	2	1	52	60	9	2	0	1	0	34	186	225	411
Total	7,010	4,123	548	17,540	26,226	2,198	3,060	463	4,441	1,327	307	67,243	58,082	125,325

^{*}Third quarter 2009 data is for an incomplete quarter.

Exhibit 3 Page 3

								Pa	age 3					
Table 8														
	Compensation	Actual Dollars	Paid By Qua	arter										RECA Benefits Paid
Paid Qtr No Date	RECA 200,000	BD 0	CS 0	CN-SEC 0 150,000	ON-NONSEC	BS 0	OL 0	RN 0	OTHER 0	99 0	PA 0	PART E	TOTAL 350,000	on Behalf of DOJ
3Q 2001	2,600,000	150,000	0	5,100,000	ō	0	0	0	0	0	0	0	7,850,000	
4Q 2001 1Q 2002	34,150,000 22,150,000	4,650,000 11,627,592	150,000 1,350,000	22,950,000 60,450,000	0	0	0	0	0	0	0	0	61,900,000 95,577,592	
2Q 2002 3Q 2002	18,550,000 14,445,000	25,487,957 18,246,037	1,800,000 450,000	52,650,000 58,800,000	0 450.000	0	0	0	0	0	0	0	98,487,957 92,391,037	
4Q 2002	13,550,000	17,700,000	300,000	50,400,000	900,000	0	0	0	0	0	0	0	82,850,000	
1Q 2003 2Q 2003	13,227,020 6,445,000	19,186,894 12,121,872	900,000	56,700,000 52,200,000	300,000 4,500,000	0	0	0	0	0	0	0	90,313,914 75,866,872	
3Q 2003 4Q 2003	5,900,000 5,730,000	9,554,240 8,850,000	600,000 150,000	26,700,000 26,375,000	14,550,000 20,700,000	0	0	0	0	0	0	0	57,304,240 61,805,000	
1Q 2004	7,200,000	14,483,172	150,000	23,700,000	18,750,000	0	0	0	0	0	0	0	64,283,172	
2Q 2004 3Q 2004	8,150,000 7,790,000	10,500,000 10,350,000	0 450,000	24,425,000 26,250,000	17,962,500 16,500,000	0	0	0	0	0	0	0	61,037,500 61,340,000	
4Q 2004 1Q 2005	4,400,000 8,850,000	7,875,000 11,250,000	150,000 450,000	23,250,000 26,700,000	27,450,000 26,200,000	0	0	0	0	0	0	125,000 31,350,000	63,250,000 104,800,000	13.333.333
2Q 2005	9,400,000	9,300,000	750,000	22,245,000	37,500,000	0	0	0	0	0	0	38,475,000	117,670,000	20,734,838
3Q 2005 4Q 2005	6,626,669 5,338,889	6,600,000 5,400,000	300,000 300,000	45,825,000 45,982,500	53,925,000 36,450,000	0	0	0	0	0	0	130,258,207 71,199,731	243,534,876 164,671,120	22,950,000 16,916,667
1Q 2006	6,550,000	5,550,000	300,000	52,840,000 54,989,127	52,400,000	0	0	0	0	0	0	50,448,975 78,524,479	168,088,975	15,091,667 13,633,333
2Q 2006 3Q 2006	4,900,000 7,100,000	9,750,000 9,000,000	150,000 150,000	50,521,250	56,784,597 55,498,350	0	0	0	0	0	0	81,577,715	205,098,204 203,847,315	35,900,000
4Q 2006 1Q 2007	5,600,000 11.533.333	5,850,000 5,700,000	150,000 450.000	37,375,000 60.445,000	45,650,000 51,550,000	0	0	0	0	0	0	66,477,459 80,299,272	161,102,459 209,977,605	19,625,000 28,816,667
2Q 2007	16,700,000	5,387,500	450,000	59,518,393	44,637,500	0	0	0	0	0	0	103,861,967	230,555,360	17,780,000
3Q 2007 4Q 2007	17,737,500 13,150,000	6,272,663 4,800,000	750,000 450,000	62,561,250 77,710,714	28,132,500 21,000,000	0	0	0	0	0	0	122,881,499 116,050,013	238,335,412 233,160,727	11,604,571 11,844,286
1Q 2008 2Q 2008	9,783,333 5,475,000	5,362,500 4,125,000	150,000 300,000	87,227,143 72,300,357	25,100,000 27,303,571	0	0	0	0	0	0	105,841,905 122,814,421	233,464,881 232,318,350	13,220,000 11,900,000
3Q 2008	8,140,000	7,260,000	150,000	90,620,000	32,100,000	0	Ö	0	0	0	0	127,724,519	265,994,519	8,411,111
4Q 2008 1Q 2009	6,564,286 6,410,417	6,000,000 4,500,000	150,000 600,000	117,087,500 81,554,093	19,575,000 17,265,000	0	0	0	0	0	0	120,712,419 94,020,937	270,089,205 204,350,447	11,505,000 7,680,000
2Q 2009 3Q 2009	4,780,000 720,833	3,420,000 450,000	300,000	64,549,562 9,846,071	17,781,250 3,320,000	0	0	0	0	0	0	90,658,600 15,075,763	181,489,412 29,412,668	8,742,424 2,500,000
Compensation Paid as of 7/2009	319,847,280	286,760,426	13,350,000	1,629,997,961	//4,235,269	0	0	0	0	0	0	1,648,377,881	4,6/2,568,81/	292,188,897
Table 9														
Paid Qtr	Number of Cas	ses Paid Comp	ensation By	Quarter										
No Date	RECA 4	BD 0	CS 0	CN-SEC 0	ON-NONSEC	BS 0	OL 0	RN 0	OTHER 0	99 0	PA 0	PART E	TOTAL 5	
3Q 2001	52	1	0	34	0	ō	0	0	0	0	0	0	87	
4Q 2001 1Q 2002	683 439	31 78	1 9	153 403	0	0	0	0	0	0	0	0	868 929	
2Q 2002	367	173	12	351	0	0	0	0	0	0	0	0	903	
3Q 2002 4Q 2002	289 265	123 118	3 2	392 336	3 6	0	0	0	0	0	0	0	810 727	
1Q 2003 2Q 2003	260 125	128 81	6	378 348	2 30	0	0	0	0	0	0	0	774 588	
3Q 2003	116	65	4	178	97	0	0	0	0	0	0	0	460	
4Q 2003 1Q 2004	111 144	59 97	1	176 158	138 125	0	0	0	0	0	0	0	485 525	
2Q 2004 3Q 2004	161 156	70 69	0	164 175	120 110	0	0	0	0	0	0	0	515 513	
4Q 2004	88	53	1	155	183	0	0	0	0	0	0	2	482	
1Q 2005 2Q 2005	173 184	75 62	3 5	178 149	175 250	0	0	0	0	0	0	246 304	850 954	
3Q 2005 4Q 2005	133 105	44 36	2	306 307	360 243	0	0	0	0	0	0	1003 548	1,848 1,241	
1Q 2006	129	37	2	353	350	0	0	0	0	0	0	386	1,257	
2Q 2006 3Q 2006	96 142	65 60	1	367 338	379 371	0	0	0	0	0	0	610 632	1,518 1,544	
4Q 2006 1Q 2007	112 231	39 38	1 3	251 404	305 344	0	0	0	0	0	0	540 678	1,248 1,698	
2Q 2007	332	37	3	399	299	0	0	0	0	0	0	906	1,976	
3Q 2007 4Q 2007	348 261	42 32	5	420 520	189 140	0	0	0	0	0	0	1094 1063	2,098 2,019	
1Q 2008 2Q 2008	192 110	36 28	1 2	585 485	168 183	0	0	0	0	0	0	959 1160	1,941 1,968	
3Q 2008	159	49	1	611	215	0	Ö	0	0	0	0	1271	2,306	
4Q 2008 1Q 2009	130 129	40 30	1 4	784 551	131 116	0	0	0	0	0	0	1217 979	2,303 1,809	
2Q 2009 3Q 2009	96 15	23 3	2	442 69	120 23	0	0	0	0	0	0	1016 170	1,699 280	
			89											
Compensation Cases Paid as of 7/2009	6,337	1,922	89	10,921	5,175	0	0	0	0	0	0	14,784	39,228	
Table 10												24,444		
Paid Qtr	Number of Pai	d Cases Filed E	By Living Em	iployee (Not Su	ırvivor)									BS Cases Approved By
No Date	RECA	BD 0	CS 0	CN-SEC 0	ON-NONSEC 0	BS 0	OL 0	RN 0	OTHER 0	99 0	PA 0	PART E*	TOTAL	Approved By Approval Quarter 0
3Q 2001	36	0	ő	13	0	0	0	0	0	0	0	0	49	0
4Q 2001 1Q 2002	290 108	30 71	1	83 177	0	0	0	0	0	0	0	0	404 362	0 12
2Q 2002	82	139	5	115	0	0	0	0	0	0	0	0	341	42
3Q 2002 4Q 2002	109 100	81 88	3 1	131 103	0 2	0	0	0	0	0	0	0	324 294	83 163
1Q 2003 2Q 2003	82 50	73 42	3 4	100 86	0 8	0	0	0	0	0	0	0	258 190	130 54
3Q 2003	41	31	0	44	13	0	0	0	0	0	0	0	129	48
4Q 2003 1Q 2004	62 79	25 46	0	53 52	41 37	0	0	0	0	0	0	0	181 215	27 31
2Q 2004 3Q 2004	83 79	34 33	0	44 50	29 33	0	0	0	0	0	0	0	190 198	26 24
4Q 2004	51	19	0	57	61	0	0	0	0	0	0	0	188	23
1Q 2005 2Q 2005	110 122	30 26	2 5	38 55	57 79	0	0	0	0	0	0	0	237 287	12 19
3Q 2005 4Q 2005	97 81	22 17	0 2	77 103	103 78	0	0	0	0	0	0	2 7	301 288	16 15
1Q 2006	92	19	2	101	130	0	0	0	0	0	0	15	359	15
2Q 2006 3Q 2006	65 105	40 26	1	108 113	153 158	0	0	0	0	0	0	35 64	402 467	13 19
4Q 2006 1Q 2007	78 155	19 19	0	88 93	140 116	0	0	0	0	0	0	109 202	434 585	27 39
2Q 2007	257	13	1	95	122	0	0	0	0	0	ō	390	878	52
3Q 2007 4Q 2007	237 142	19 17	4	126 155	72 47	0	0	0	0	0	0	580 572	1,038 936	54 45
1Q 2008 2Q 2008	112 67	19 18	0	147 132	69 76	0	0	0	0	0	0	498 724	845 1,018	42 43
3Q 2008	102	31	1	194	84	0	Ö	0	0	0	0	781	1,193	29
4Q 2008 1Q 2009	80 74	25 24	0 2	211 129	63 50	0	0	0	0	0	0	757 683	1,136 962	42 17
2Q 2009 3Q 2009	52 3	14 2	1 0	144 24	59 13	0	0	0	0	0	0	783 126	1,053 168	30 9
		-												
Total Number as of 7/2009	3,284	1,112	53	3,241	1,893	0	0	0	0	0	0	6,328	15,911	1,201
												9,583		

*Third quarter 2009 data is for an incomplete quarter.

24 10/7/2009

DATABASE SUMMARY INFORMATION As of approximately 7/27/2009

Exhibit 3 Page 4

Tab	N۵	1.	1

Paid Qtr	Medical Actua	l Dollars Paid	By Quarter										
	RECA	BD	CS	CN-SEC	CN-NONSEC	BS	OL	RN	OTHER	99	Blank	Part E	TOTAL
	-230,230	-352,074	-22,026	-553,902	-101,910	-29,622	0	0	0	0	0	-69,723	-1,359,487
3Q 2001	0	0	0	0	0	0	0	0	0	0	0	0	0
4Q 2001	800	0	0	1,354	0	0	0	0	0	0	0	0	2,153
1Q 2002	82,905	1,845	225	217,818	0	0	0	0	0	0	0	0	302,794
2Q 2002	85,981	29,794	4,845	1,415,875	0	506	0	0	0	0	0	0	1,537,000
3Q 2002	186,475	136,938	4,456	1,644,930	1,297	6,284	0	0	0	0	0	74	1,980,454
4Q 2002	201,816	230,965	12,642	1,272,103	3,694	21,889	0	0	0	0	0	391	1,743,499
1Q 2003	391,191	862,492	6,842	2,020,038	29,431	120,875	0	0	360	0	0	6,767	3,437,996
2Q 2003	729,448	1,056,419	19,551	2,288,713	21,720	210,268	750	0	0	0	0	7,408	4,334,275
3Q 2003	1,092,352	786,075	18,076	3,084,031	35,344	197,738	0	0	450	0	0	9,222	5,223,288
4Q 2003	937,513	487,098	40,416	2,531,516	51,597	123,673	0	0	0	0	0	7,128	4,178,941
1Q 2004	1,249,458	980,982	43,537	4,486,358	169,658	230,522	0	0	0	0	0	11,263	7,171,777
2Q 2004	1,256,372	812,486	43,704	3,997,496	125,188	188,376	0	0	0	600	0	19,768	6,443,989
3Q 2004	1,250,506	609,576	24,183	2,975,627	210,135	115,149	0	0	630	0	0	22,034	5,207,840
4Q 2004	2,798,399	738,317	29,987	2,892,098	273,744	91,523	0	0	0	200	0	8,803	6,833,070
1Q 2005	3,918,187	556,928	43,499	3,038,001	273,938	80,572	0	0	0	0	0	20,830	7,931,955
2Q 2005	4,207,671	876,746	29,530	3,310,522	443,974	153,564	0	0	570	0	0	42,798	9,065,376
3Q 2005	3,691,239	1,008,758	44,802	3,379,561	581,264	136,277	400	0	0	0	0	105,139	8,947,440
4Q 2005	2,420,970	860,165	71,443	3,595,667	598,923	144,250	0	0	0	0	0	164,217	7,855,636
1Q 2006	5,134,562	794,985	79,239	3,895,692	654,864	88,202	146	0	250	0	0	682,649	11,330,589
2Q 2006	4,997,519	835,223	103,439	3,980,363	1,485,979	109,581	0	0	1,820	0	0	657,755	12,171,679
3Q 2006	3,692,906	1,001,221	70,748	3,606,309	975,085	114,058	0	0	967	0	375	814,259	10,275,928
4Q 2006	3,067,159	868,194	58,885	3,358,779	999,405	126,146	1,050	0	225	0	2,325	921,600	9,403,769
1Q 2007	4,547,307	977,996	69,057	4,846,738	1,624,787	86,399	2,850	0	2,650	900	0	1,251,742	13,410,427
2Q 2007	6,701,169	1,051,154	76,203	6,159,044	1,874,649	122,349	4,815	0	4,519	450	0	1,342,017	17,336,369
3Q 2007	6,630,057	1,207,720	91,264	8,114,108	2,495,018	209,132	4,691	0	4,670	900	0	1,587,697	20,345,258
4Q 2007	10,457,107	1,973,358	138,128	12,381,504	3,406,657	325,556	20,101	0	7,721	1,800	0	3,714,228	32,426,159
1Q 2008	5,825,866	1,445,180	107,279	6,684,999	1,865,574	229,761	4,917	0	2,114	0	0	1,640,630	17,806,320
2Q 2008	6,492,837	1,894,101	82,387	6,888,016	2,089,742	141,027	9,165	0	2,214	0	0	1,929,996	19,529,486
3Q 2008	6,734,903	1,396,064	89,355	8,045,711	3,346,606	198,454	8,403	0	2,832	0	3,975	3,487,692	23,313,996
4Q 2008	8,750,907	1,348,455	82,339	9,470,257	3,091,971	267,878	11,507	0	10,517	0	1,565	3,864,617	26,900,012
1Q 2009	8,081,153	2,047,541	84,633	8,419,718	3,352,695	234,879	12,218	0	3,414	0	538	3,972,359	26,209,149
2Q 2009	3,808,843	1,094,576	55,226	4,852,298	2,190,744	117,084	8,052	0	1,692	0	1,200	3,051,734	15,181,449
3Q 2009	3,046,565	891,653	48,692	3,558,725	1,311,056	72,756	7,943	0	1,131	0	0	1,885,276	10,823,797
Medical Paid as of 7/2009	112,239,914	28,510,931	1,652,586	135,860,065	33,482,830	4,235,102	97,008	0	48,746	4,850	9,978	31,160,371	347,302,382

Table 12

Paid Qtr	Number of Case	s Paid Medical	By Quarter	r									
	RECA	BD	CS	CN-SEC CN	N-NONSEC	BS	OL	RN	OTHER	99	Blank	Part E	TOTAL
No Date	401	267	17	446	164	46	0	0	0	0	0	117	1,458
3Q 2001	0	0	0	0	0	0	0	0	0	0	0	0	0
4Q 2001	3	0	0	5	0	0	0	0	0	0	0	0	8
1Q 2002	24	5	1	36	0	0	0	0	0	0	0	0	66
2Q 2002	42	25	2	76	0	1	0	0	0	0	0	0	146
3Q 2002	57	79	3	139	5	7	0	0	0	0	0	2	292
4Q 2002	69	80	5	172	5	23	0	0	0	0	0	2	356
1Q 2003	119	191	6	266	22	43	0	0	1	0	0	17	665
2Q 2003	170	246	8	332	21	65	1	0	0	0	0	11	854
3Q 2003	217	275	12	384	26	72	0	0	1	0	0	11	998
4Q 2003	261	283	11	378	22	74	0	0	0	0	0	8	1,037
1Q 2004	276	345	12	464	53	87	0	0	0	0	0	26	1,263
2Q 2004	290	368	9	485	67	89	0	0	0	1	0	41	1,350
3Q 2004	317	394	11	504	83	74	0	0	1	0	0	59	1,443
4Q 2004	376	367	12	504	81	68	0	0	0	1	0	28	1,437
1Q 2005	417	406	13	552	109	68	0	0	0	0	0	49	1,614
2Q 2005	512	447	12	610	137	98	0	0	2	0	0	43	1,861
3Q 2005	544	459	15	615	174	115	1	0	0	0	0	91	2,014
4Q 2005	612	456	19	663	190	102	0	0	0	0	0	95	2,137
1Q 2006	646	445	23	705	226	76	1	0	1	0	0	128	2,251
2Q 2006	685	532	28	868	342	93	0	0	2	0	0	440	2,990
3Q 2006	708	496	26	912	431	96	0	0	2	0	1	776	3,448
4Q 2006	752	496	28	877	456	98	1	0	1	0	2	741	3,452
1Q 2007	782	498	26	944	492	88	2	0	2	1	0	754	3,589
2Q 2007	983	549	33	1,092	605	121	5	0	4	1	0	891	4,284
3Q 2007	1,270	578	36	1,280	717	144	6	0	3	1	0	1,205	5,240
4Q 2007	1,560	688	45	1,735	961	233	10	0	5	1	0	1,776	7,014
1Q 2008	1,119	525	39	1,146	624	169	5	0	3	0	0	1,001	4,631
2Q 2008	1,184	532	35	1,238	740	127	5	0	2	0	0	1,180	5,043
3Q 2008	1,282	582	29	1,286	753	165	6	0	3	0	2	1,345	5,453
4Q 2008	1,367	603	34	1,427	815	179	7	0	3	0	2	1,546	5,983
1Q 2009	1,263	572	36	1,406	784	171	10	0	3	0	2	1,461	5,708
2Q 2009	1,131	497	30	1,264	674	138	8	0	2	0	1	1,223	4,968
3Q 2009	894	432	26	1,021	511	94	10	0	3	0	0	998	3,989
Medical Cases Paid as of 7/2009	20,333	12,718	642	23,832	10,290	3,024	78	0	44	6	10	16,065	87,042

Cases are counted in every quarter with a medical payment so they may be counted multiple times

Note: Medical payments are coded to case and therefore cannot be allocated between Parts B and E. Medical is counted as Part E only if there is no Part B claim or if the Part B claim is denied and the Part E claim is approved.

^{*}Third quarter 2009 data is for an incomplete quarter.

Estimation of Part E Average Cost Per case

Benefits Paid to Employee

Im	pairme	nt Bei	nefits

Amount of Benefit				
	Less Than Or	Number of	Total Amount	Average
Greater Than	Equal To	Cases	Paid	Amount Paid
0	50,000	2462	60,504,088	24,575
50,000	100,000	1525	111,730,755	73,266
100,000	150,000	1067	133,839,309	125,435
150,000	200,000	556	98,447,079	177,063
200,000	250,000	398	91,216,668	229,188
Total		6008	495,737,899	82,513

Lump Sums

Amount of Benefit

	Less Than Or	Number of	Total Amount	Average
Greater Than	Equal To	Cases	Paid	Amount Paid
0	50,000	1	50,000	50,000
50,000	100,000	1	72,500	72,500
100,000	150,000	2	257,500	128,750
150,000	200,000	0	0	
200,000	250,000	1	207,500	207,500
Total		5	587,500	117,500

Wage Loss Benefits

Amount of Benefit

	Less Than Or	Number of	Total Amount	Average
Greater Than	Equal To	Cases	Paid	Amount Paid
0	50,000	145	4,227,625	29,156
50,000	100,000	123	8,781,478	71,394
100,000	150,000	66	8,200,205	124,246
150,000	200,000	30	5,173,845	172,462
200,000	250,000	17	3,958,985	232,881
Total		381	30,342,138	79,638

Additional wage loss benefits may be paid to employees below the normal retirement age.

Total Employee Benefit

Amount of Benefit

	Less Than Or	Number of	Total Amount	Average
Greater Than	Equal To	Cases	Paid	Amount Paid
0	50,000	2,430	59,673,914	24,557
50,000	100,000	1,467	107,358,392	73,182
100,000	150,000	1,048	131,411,301	125,392
150,000	200,000	566	100,716,798	177,945
200,000	250,000	546	127,506,925	233,529
Total		6,057	526,667,330	86,952

Maximum Total Benefit, excluding medical, for impairment, wage loss and survivorship is \$250,000.

Benefits Paid to Survivor

Amount of Benefit

	Less Than Or	Number of	Total Amount	Average
Greater Than	Equal To	Cases	Paid	Amount Paid
0	50,000	100	2,790,038	27,900
50,000	100,000	241	17,157,612	71,193
100,000	150,000	8,162	1,038,727,870	127,264
150,000	200,000	356	62,314,406	175,040
200,000	250,000	3	720,625	240,208
Total		8.862	1.121.710.551	126.575

Selection of Average Part E Benefit

Employee Survivor	60% 70%	\$90,000 \$128.000
Average	70%	\$144,000
Selected		\$143,000

Assumes 50% of employees that have received awards will die from covered condition and have eligible survivor to receive award.

The employee benefit is selected based on payments to date. Some employees will receive additional wage loss payments but also some claims are accepted for medical payments only with no impairment.

PROJECTED APPROVED CASES BY QUARTER FILED FOR RECA CASES

CASES BY QUARTER

	(1)	(2)	(3) (4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8) Estimated	(10)	(11) =(9) x (10) Estimated	(12) Approved
Quarter			Number of	Judgmental			Selected	Approved	Case	Ultimate	Cases By
Filed	Year	t	Cases	Adjustment	у	In(y)	Approval Rate	Cases	Amount	Compensation	Fiscal Year
3	2001		1,536 Actual	0	1536	7.33694	0.95	1459	50,000	72,950,000	1,459
4 1	2001 2002	1 2	348 Actual 284 Actual	0	348 284	5.85220 5.64897	0.95 0.95	331 270	50,000 50,000	16,550,000 13,500,000	0
2	2002	3	251 Actual	0	251	5.52545	0.95	238	50,000	11,900,000	0
3	2002	4	201 Actual	0	201	5.30330	0.95	191	50,000	9,550,000	1,030
4	2002	5	154 Actual	0	154	5.03695	0.95	146	50,000	7,300,000	0
1 2	2003 2003	6 7	106 Actual 134 Actual	0	106 134	4.66344 4.89784	0.95 0.95	101 127	50,000 50,000	5,050,000 6,350,000	0
3	2003	8	120 Actual	0	120	4.78749	0.95	114	50,000	5,700,000	488
4	2003	9	155 Actual	0	155	5.04343	0.95	147	50,000	7,350,000	0
1	2004	10	199 Actual	0	199	5.29330	0.95	189	50,000	9,450,000	0
2	2004	11	121 Actual	0	121	4.79579	0.95	115	50,000	5,750,000	0
3 4	2004 2004	12 13	139 Actual 155 Actual	0	139 155	4.93447 5.04343	0.95 0.95	132 147	50,000 50,000	6,600,000 7,350,000	583 0
1	2005	14	211 Actual	0	211	5.35186	0.95	200	50,000	10,000,000	0
2	2005	15	273 Actual	0	273	5.60947	0.95	259	50,000	12,950,000	0
3	2005	16	220 Actual	0	220	5.39363	0.95	209	50,000	10,450,000	815
4 1	2005 2006	17	167 Actual	0	167 185	5.11799 5.22036	0.95	159	100,000	15,900,000	0
2	2006	18 19	185 Actual 143 Actual	0	143	4.96284	0.95 0.95	176 136	100,000 100,000	17,600,000 13,600,000	0
3	2006	20	310 Actual	0	310	5.73657	0.95	295	150,000	44,250,000	766
4	2006	21	222 Actual	0	222	5.40268	0.95	211	150,000	31,650,000	0
1	2007	22	228 Actual	0	228	5.42935	0.95	217	150,000	32,550,000	0
2	2007 2007	23 24	177 Actual	0	177 123	5.17615	0.95 0.95	168 117	150,000 150,000	25,200,000	0 713
4	2007	25	123 Actual 152 Actual	0	152	4.81218 5.02388	0.95	144	150,000	17,550,000 21,600,000	713
1	2008	26	150 Actual	0	150	5.01064	0.95	143	150,000	21,450,000	0
2	2008	27	136 Actual	0	136	4.91265	0.95	129	150,000	19,350,000	0
3	2008	28	115 Actual	0	115	4.74493	0.95	109	150,000	16,350,000	525
4 1	2008 2009	29 30	95 Actual 80 Actual	0	95 80	4.55388 4.38203	0.95 0.95	90 76	150,000 150,000	13,500,000 11,400,000	0
2	2009	31	95 Actual	0	95	4.55388	0.95	90	150,000	13,500,000	0
3	2009	32	90 Projected				0.95	86	150,000	12,900,000	342
4	2009	33	87 Projected				0.95	83	150,000	12,450,000	0
1	2010	34	84 Projected				0.95	80	150,000	12,000,000	0
2 3	2010 2010	35 36	80 Projected 77 Projected				0.95 0.95	76 73	150,000 150,000	11,400,000 10,950,000	0 312
4	2010	37	75 Projected				0.95	71	150,000	10,650,000	0
1	2011	38	72 Projected				0.95	68	150,000	10,200,000	0
2	2011	39	69 Projected				0.95	66	150,000	9,900,000	0
3	2011	40	67 Projected				0.95	64	150,000	9,600,000	269
4 1	2011 2012	41 42	64 Projected 62 Projected				0.95 0.95	61 59	150,000 150,000	9,150,000 8,850,000	0
2	2012	43	60 Projected				0.95	57	150,000	8,550,000	0
3	2012	44	57 Projected				0.95	54	150,000	8,100,000	231
4	2012	45	55 Projected				0.95	52	150,000	7,800,000	0
1 2	2013 2013	46 47	53 Projected 51 Projected				0.95 0.95	50 48	150,000 150,000	7,500,000 7,200,000	0
3	2013	48	49 Projected				0.95	47	150,000	7,050,000	197
4	2013	49	48 Projected				0.95	46	150,000	6,900,000	0
1	2014	50	46 Projected				0.95	44	150,000	6,600,000	0
2	2014	51	44 Projected				0.95	42	150,000	6,300,000	0
3 4	2014 2014	52 53	43 Projected 41 Projected				0.95 0.95	41 39	150,000 150,000	6,150,000 5,850,000	173 0
1	2015	54	39 Projected				0.95	37	150,000	5,550,000	0
2	2015	55	38 Projected				0.95	36	150,000	5,400,000	0
3	2015	56	37 Projected				0.95	35	150,000	5,250,000	147
4 1	2015 2016	57 58	35 Projected 34 Projected				0.95 0.95	33 32	150,000 150,000	4,950,000 4,800,000	0
2	2016	59	33 Projected				0.95	31	150,000	4,650,000	0
3	2016	60	32 Projected				0.95	30	150,000	4,500,000	126
4	2016	61	30 Projected				0.95	29	150,000	4,350,000	0
1	2017	62	29 Projected				0.95	28	150,000	4,200,000	0
3	2017 2017	63 64	28 Projected 27 Projected				0.95	27 26	150,000	4,050,000 3,900,000	110
4	2017	65	26 Projected				0.95	25	150,000	3,750,000	0
1	2018	66	25 Projected				0.95	24	150,000	3,600,000	0
2	2018	67	24 Projected				0.95	23	150,000	3,450,000	0
3	2018	68	23 Projected				0.95	22	150,000	3,300,000	94
4 1	2018 2019	69 70	22 Projected 22 Projected				0.95 0.95	21 21	150,000 150,000	3,150,000 3,150,000	0
2	2019	71	21 Projected				0.95	20	150,000	3,000,000	0
3	2019	72	20 Projected				0.95	19	150,000	2,850,000	81
4	2019	73	19 Projected				0.95	18	150,000	2,700,000	0
1	2020	74 75	19 Projected				0.95	18	150,000	2,700,000	0
2	2020 2020	75 76	18 Projected 17 Projected				0.95 0.95	17 16	150,000 150,000	2,550,000 2,400,000	0 69
4	2020	77	17 Projected				0.95	16	150,000	2,400,000	0
1	2021	78	16 Projected				0.95	15	150,000	2,250,000	0
2	2021	79	15 Projected				0.95	14	150,000	2,100,000	0
3	2021	80	15 Projected				0.95	14	150,000	2,100,000	59

PROJECTED APPROVED CASES BY QUARTER FILED FOR RECA CASES

Exhibit 4

Parameters for fitted curve m -0.0186 5.4014 b Starting 3Q 2004 m -0.0389 5.9048 b Selected Parameters for m -0.0375 5.7000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
						= (3) + (5)			=(4) x (8) Estimated		=(9) x (10)	A
Quarter			Number of		li idama antal			Selected		Case	Estimated Ultimate	Approved Cases By
Filed	Year	t	Cases		Judgmental		Im (v.)		Approved Cases	Amount		Fiscal Year
Filed 4	7 ear 2021	ر 81		Projected	Adjustment	У	In(y)	Approval Rate 0.9			Compensation 1,950,000	o 0
	2021											
1 2	2022	82 83		Projected Projected				0.9 0.9			1,950,000 1,800,000	0
3	2022	84		Projected				0.9			1,800,000	0 50
4	2022	85		Projected				0.9		150,000	1,650,000	0
1	2022	86		Projected				0.9		150,000	1,650,000	0
2	2023	87		Projected				0.9			1,500,000	0
3	2023	88		Projected				0.9			1,500,000	42
4	2023	89		Projected				0.9			1,500,000	0
1	2023	90		Projected				0.9			1,500,000	0
	2024	91						0.9			1,500,000	0
2	2024	92		Projected				0.9				39
	2024			Projected							1,350,000	
4	2024	93 94		Projected				0.9 0.9			1,350,000 1,350,000	0
1 2	2025	94 95		Projected				0.9		150,000 150,000		0
3	2025	96		Projected				0.9			1,200,000	34
				Projected							1,200,000	
4	2025	97		Projected				0.9		150,000	1,200,000	0
1 2	2026	98 99		Projected				0.9 0.9			1,200,000	0
3	2026 2026	100		Projected				0.9			1,050,000	0
				Projected							1,050,000	30
4	2026 2027	101 102		Projected				0.9 0.9			1,050,000	0
1 2	2027	102		Projected Projected				0.9			1,050,000 900,000	0
3	2027	103		Projected				0.9			900,000	
4	2027	104		Projected				0.9			900,000	26 0
1	2027	105		Projected				0.9		150,000	900,000	0
2	2028	107		Projected				0.9			750,000	0
3	2028	107		Projected				0.9			750,000	22
4	2028	109		Projected				0.9			750,000	0
1	2029	110		Projected				0.9			750,000	0
2	2029	111		Projected				0.9			750,000	0
3	2029	112		Projected				0.9		150,000	600,000	19
4	2029	113		Projected				0.9			600,000	0
1	2030	114		Projected				0.9			600,000	0
2	2030	115		Projected				0.9		150,000	600,000	0
3	2030	116		Projected				0.9			600,000	16
3	2030	110	4	i iojecieu				0.5	J 4	130,000	000,000	10
			9,327						8,867		869,000,000	8,867

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM DISEASE CASES

Parameters for fitted curve m -0.0892 5.7472 b Starting 3Q 2004 m -0.0906 5.7747 b Parameters Selected for m -0.0892 5.7472 b

CASES BY QUARTER

Fleed Vest Caise Adjustment Adjustment Sept		(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Filed Very Case Number of Number of Number of New													Approved
Filed Veal	_										_		
3 2001		.,											
4 2001 1 9SS Actual 0 3SS 586847 0.53 187 150,000 28,050,000 0 0 1 1 2000 2 2 31 Actual 0 341 Actual 0 341 583188 0.53 134 150,000 27,150,000 0 0 3 2000 2 3 2KS Actual 0 2SS 553599 0.53 134 150,000 20,110,000 0 76 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			t										
1 2002 2 341 Actual 0 341 583188 0.53 181 150,000 271,50,000 0 0 0 2 2 2 2 2 2													
2 2002 3 3 253 Actual 0 253 5.55339 0.53 134 150,000 20.100,000 0 76 1 3 3 2002 4 1 100 Actual 0 140 Actual 0 140 Actual 0 150 4.94164 0.53 74 150,000 11,000 0 76 1 2 2003 6 130 Actual 0 140 Actual 0 140 140													
3 2002 4 140 Actual 0 140 494164 0.53 74 150,000 11,100,000 576 4 2002 5 168 Actual 0 168 512360 0.53 89 150,000 10,350,000 0 0 1 2 2003 8 1 100 Actual 0 130 486753 0.53 89 150,000 10,350,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
4 2002 5 168 Actual 0 168 51/2396 0.53 89 150,000 0 13,550,000 0 2 2003 6 7 125 Actual 0 126 48,82831 0.53 68 150,000 3,900,000 0 0 0 0 0 0 0 0													
1 2003 6 130 Actual 0 130 4.86753 0.53 69 150,000 10,350,000 0 0 0 0 0 0 0 0													
2 2003 7 1 125 Actual 0 125 4,82831 0.53 66 150,000 9,900,000 0 0 0 0 0 0 0 0 0 0 0 0													
3 2003 8 147 Actual 0 147 499043 0.53 78 150,000 11,700,000 302 14 2003 9 153 Actual 0 153 50,504 0.53 16 150,000 11,700,000 0 0 12,700,000 10													
4 2004 10 198 Actual 0 153 5.03044 0.53 81 150,000 12,150,000 0 0 1 1 1 2004 10 198 Actual 0 185 5.03527 0.53 87 150,000 13,050,000 0 383 1 2 2 2004 11 165 Actual 0 207 5.32272 0.53 87 150,000 15,500,000 0 383 1 2 2 207 Actual 0 207 5.32272 0.53 87 150,000 15,500,000 0 383 1 2 2 207 Actual 0 207 5.32272 0.53 87 150,000 15,500,000 0 0 15,500,000 0 0 15,500,000 0 0 1 1 2 205 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1													
1 2004 10 198 Actual 0 198 5.28867 0.53 105 150.000 15.050,000 0 0 0 0 0 0 0 0													
2 2004 11 165 Actual 0 165 5.10595 0.53 87 150,000 13,050,000 0 883 84 2004 12 207 Actual 0 27 5.3272 0.53 10 150,000 15,500,000 383 84 2004 13 89 Actual 0 89 4.48864 0.53 47 150,000 7,050,000 0 0 12,000,000 0 0 12,000,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
3 2004 12 207 Actual 0 207 5.33272 0.53 110 150,000 155,000,000 383 4.8													
4 2004 13 88 Actual 0 88 4.48864 0.53 47 150.000 7,050.000 0 1 1 2005 14 128 Actual 0 126 4.88628 0.53 47 150.000 7,050.000 0 0 2 2 2005 15 98 Actual 0 98 4.58467 0.53 52 150.000 7,800,000 0 208 1 2 2 2005 17 36 Actual 0 36 3.58352 0.53 19 150.000 2,800,000 0 0 1 2 2 2006 18 42 Actual 0 42 37.757 0.53 52 150.000 2,800,000 0 0 1 2 2 2006 19 3 44 Actual 0 42 37.757 0.53 52 150.000 2,800,000 0 0 1 2 2 2006 19 3 44 Actual 0 42 37.757 0.53 12 150.000 2,800,000 0 0 1 2 2 2006 2 19 3 44 Actual 0 42 37.757 0.53 2 2 150.000 2,800,000 0 0 1 2 2 2006 2 1 4 Actual 0 42 37.757 0.53 2 2 150.000 2,800,000 0 0 1 2 2 2007 2 3 44 Actual 0 44 3.7419 0.53 2 1 50.000 3,300,000 0 0 1 2 2 2007 2 3 44 Actual 0 44 3.7419 0.53 2 1 50.000 3,300,000 0 0 1 2 2 2007 2 3 44 Actual 0 44 3.7419 0.53 2 1 50.000 3,300,000 0 0 1 2 2 200 2 2 2 40 Actual 0 45 3.7419 0.53 2 1 50.000 3,300,000 0 0 1 2 2 200 2 2 2 40 Actual 0 45 3.7419 0.53 2 1 50.000 3,300,000 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2													
1 2005													
2 2005 15 98 Actual 0 98 4.58497 0.53 S2 150,000 7.800,000 0 208 4 2005 17 36 Actual 0 79 4.38945 0.53 42 150,000 6.300,000 0 208 4 2006 17 36 Actual 0 36 3.58352 0.53 12 150,000 3.300,000 0 0 2 2 2006 19 34 Actual 0 34 3.52836 0.53 12 150,000 3.300,000 0 1 4 2 3.73767 0.53 22 150,000 3.300,000 0 1 4 2 2 2006 19 34 Actual 0 42 3.73767 0.53 22 150,000 3.300,000 0 1 1 2007 22 49 Actual 0 42 3.73767 0.53 22 150,000 3.300,000 0 1 2 2 2007 23 44 Actual 0 44 3.78419 0.53 26 150,000 3.300,000 0 0 2 2 2007 23 44 Actual 0 44 3.78419 0.53 26 150,000 3.300,000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
3 2005 16 79 Actual 0 79 4.36945 0.53 42 150,000 2.080,000 0 0 1 2006 18 4.2 Actual 0 42 3.73767 0.53 19 150,000 2.080,000 0 0 2 2 2006 19 34 Actual 0 42 3.73767 0.53 12 150,000 2.300,000 0 0 3 3.2006 20 41 Actual 0 41 3.71357 0.53 22 150,000 3.300,000 0 0 0 0 0 0 0 0													
4 2006 17 36 Actual 0 36 3.58382 0.53 22 150,000 3.300,000 0 0 2 2.006 19 34 Actual 0 34 3.52836 0.53 22 150,000 3.300,000 0													
2 2006 19 34 Actual 0 34 3.52636 0.53 18 150,000 2,700,000 0 0 1 4 2 307367 0.53 22 150,000 3,300,000 81 4 2 2006 21 42 Actual 0 44 3,37367 0.53 22 150,000 3,300,000 0 0 1 2 2 2007 23 44 Actual 0 49 3,89162 0.53 26 150,000 3,300,000 0 0 3 3 2007 24 55 Actual 0 55 4 0,0733 0.53 29 150,000 3,350,000 10 0 1 2 2 2007 25 40 Actual 0 49 3,88888 0.53 21 150,000 3,150,000 0 0 1 2 2 2008 26 27 Actual 0 27 3,29584 0.53 14 150,000 2,100,000 0 0 2 2 2008 27 27 Actual 0 27 3,29584 0.53 14 150,000 2,100,000 0 0 2 2 2008 27 27 Actual 1 2 2 32,1888 0.53 13 150,000 1,190,000 0 0 1 2 2 2008 27 27 Actual 1 2 2 32,1888 0.53 13 150,000 1,190,000 0 0 1 2 2 2009 30 27 Actual 2 2 26 3,25810 0.53 14 150,000 1,190,000 0 0 1 2 2 2009 31 12 Actual 2 2 26 3,25810 0.53 14 150,000 2,100,000 0 0 2 2 2 2009 31 12 Actual 4 16 2,77259 0.53 16 150,000 3,000,000 0 0 1 2 2 2009 31 12 Actual 4 16 2,77259 0.53 16 150,000 1,190,000 0 0 1 2 2 2009 33 17 Projected 0 .53 18 150,000 1,150,000 0 0 1 2 2 2010 35 14 Projected 0 .53 18 150,000 1,150,000 0 0 1 2 2 2010 35 14 Projected 0 .53 18 150,000 1,150,000 0 0 1 2 2 2010 35 14 Projected 0 .53 18 150,000 1,150,000 0 0 1 2 2 2011 39 10 Projected 0 .53 18 150,000 1,150,000 0 0 1 2 2 2011 39 10 Projected 0 .53 16 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 16 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 16 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 16 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 16 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 17 150,000 1,150,000 10 2 2 2011 39 10 Projected 0 .53 18 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 18 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 18 150,000 300,000 0 0 1 2 2 2011 39 10 Projected 0 .53 18 150,000 300,000 0 0 1 2 2 2012 43 4 Projected 0 .53 18 150,000 300,000 0 0 0 1 2 2 2012 43 4 Projected 0 .53 18 150,000 300,000 0 0 0 1 2 2 2012 43 4 Projected 0 .53 18 150,000 300,000 0 0 0 1 2 2 2013 45 18 Projected 0 .53 18 150,000 300,000 0 0 0 1 2 2 2014 5 5 4 Projected 0 .53 18 150,000 150,000 0 0 0 0	4	2005	17	36 A	ctual	C	36	3.58352	0.53	19	150,000	2,850,000	0
3 2006 20	1	2006	18	42 A	ctual	C	42	3.73767	0.53	22	150,000	3,300,000	0
4 2006 21 42 Actual 0 42 3.73767 0.53 22 150,000 3.300,000 0 0 1 2007 22 49 Actual 0 49 3.89182 0.53 22 150,000 3.300,000 0 0 2 2 2007 23 44 Actual 0 54 4.0733 0.53 23 150,000 3.450,000 100 4 2 2007 25 40 Actual 0 55 4,00733 0.53 23 150,000 3.450,000 100 4 2 2007 25 40 Actual 0 55 4,00733 0.53 22 1150,000 3.150,000 0 0 1 2 2 2008 26 27 Actual 0 27 3.29584 0.53 14 150,000 2,100,000 0 2 2 2008 27 27 Actual 0 27 3.29584 0.53 14 150,000 2,100,000 0 0 2 2 2 2008 27 27 Actual 1 25 3.2188 0.53 13 150,000 1,000,000 0 0 0 0 0 0 0 0 0 0 0 0	2	2006	19	34 A	ctual	C	34	3.52636	0.53	18	150,000	2,700,000	0
1 2007 22 49 Actual 0 49 3.89182 0.53 26 150.000 3.900,000 0 0 3 2007 23 44 Actual 0 44 3.78419 0.53 22 150.000 3.450,000 0 0 3 2007 25 40 Actual 0 40 55 4.00733 0.53 29 150.000 4.350,000 100 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3	2006	20	41 A	ctual	C	41	3.71357	0.53	22	150,000	3,300,000	81
2 2007 23 44 Actual 0 54 3.78419 0.53 23 150,000 3.450,000 10 4 2007 25 5 Actual 0 55 A00733 0.53 22 1150,000 3.450,000 10 4 2007 25 40 Actual 0 55 A00733 0.53 22 1150,000 3.150,000 0 1 20 20 20 20 26 27 Actual 0 27 3.2584 0.53 14 150,000 2,100,000 0 2 20 20 20 27 Actual 1 25 3.2584 0.53 14 150,000 2,100,000 0 2 2 20 20 20 27 Actual 1 25 3.2188 0.53 11 150,000 1250,000 0 62 2 20 20 20 27 Actual 1 25 3.2188 0.53 11 150,000 1250,000 0 62 2 20 20 20 27 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 11 150,000 1950,000 0 0 2 2 Actual 2 2 26 3.25810 0.53 10 150,000 10 2 2 20 20 31 12 Actual 4 16 2.77259 0.53 16 150,000 10 2 2 20 20 31 18 Projected 0.53 16 150,000 10 2 2 20 10 35 17 Projected 0.53 7 150,000 11,050,000 0 0 2 2 20 10 35 13 Projected 0.53 7 150,000 10,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4	2006	21	42 A	ctual	C	42	3.73767	0.53	22		3,300,000	0
3 2007 24 55 Actual 0 55 4.00733 0.53 29 150,000 4.350,000 0 0 1 2008 26 27 Actual 0 27 3.25584 0.53 14 150,000 2.100,000 0 0 2 2 2.2088 27 27 Actual 0 27 3.25584 0.53 14 150,000 2.100,000 0 0 0 0 0 0 0 0	1	2007	22	49 A	ctual	C) 49	3.89182	0.53	26	150,000	3,900,000	0
4 2007 25 40 Actual 0 40 3.88888 0.53 21 150,000 3,150,000 0 1 2 2008 27 27 Actual 0 27 3,29584 0.53 14 150,000 2,100,000 0 0 2 2 2008 27 27 Actual 0 27 3,29584 0.53 14 150,000 2,100,000 0 0 3 2008 28 24 Actual 1 25 3,21888 0.53 13 150,000 1,950,000 0 62 4 2008 29 24 Actual 2 2 26 3,25510 0.53 13 150,000 1,950,000 0 0 1 2 2 2009 31 12 Actual 4 16 2,77259 0.53 6 150,000 90,000 0 0 2 2 2009 31 12 Actual 4 16 2,77259 0.53 6 150,000 90,000 0 0 1 2 2 2009 31 17 Projected 0 0.53 9 150,000 1,500,000 0 0 1 2 2 2010 35 14 Projected 0 0.53 9 150,000 1,200,000 0 0 1 2 2 2010 35 14 Projected 0 0.53 9 150,000 1,050,000 0 0 1 2 2 2010 35 14 Projected 0 0.53 7 150,000 1,050,000 0 1 2 2 2010 35 14 Projected 0 0.53 7 150,000 1,050,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 1 2 2 2011 39 10 Projected 0 0.53 6 150,000 900,000 0 2 2 2011 40 9 Projected 0 0.53 6 150,000 900,000 0 2 2 2011 40 9 Projected 0 0.53 4 150,000 600,000 0 1 2 2 2012 42 7 Projected 0 0.53 4 150,000 600,000 0 1 2 2 2012 42 7 Projected 0 0.53 4 150,000 600,000 0 0 1 2 2 2012 42 7 Projected 0 0.53 4 150,000 600,000 0 0 1 2 2 2012 43 7 Projected 0 0.53 4 150,000 600,000 0 0 1 2 2 2012 44 6 Projected 0 0.53 4 150,000 600,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2012 45 6 Projected 0 0.53 3 150,000 450,000 0 0 1 2 2 2014 51 6 Projected 0 0.53 1 150,000 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2	2007	23	44 A	ctual	C) 44	3.78419	0.53	23	150,000	3,450,000	0
1 2008 26 27 Actual 0 27 3.29584 0.53 14 150,000 2.100,000 0 0 2 2 0008 27 27 Actual 0 27 3.29584 0.53 14 150,000 2.100,000 0 0 3 2008 28 24 Actual 1 25 3.21888 0.53 13 150,000 1.950,000 62 4 2008 29 24 Actual 2 2 26 3.25510 0.53 14 150,000 1.950,000 0 0 1 200,000 0 1 2 2 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 3 2 2 2 3 2	3	2007	24	55 A	ctual	C	55	4.00733	0.53	29		4,350,000	100
2 2008 27 27 Actual 0 27 3.29584 0.53 14 150,000 2,100,000 0 62 30008 28 24 Actual 1 25 3.21888 0.53 13 150,000 1,950,000 0 62 4 2008 29 24 Actual 2 2 26 3.25510 0.53 13 150,000 1,950,000 0 0 1 2 2009 30 27 Actual 3 3 30 3.40120 0.53 14 150,000 1,950,000 0 0 2 2009 31 12 Actual 4 16 2.77259 0.53 14 150,000 900,000 0 0 3 2 2 2009 32 18 Projected 0.53 3 10 150,000 1,550,000 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	4			40 A	ctual							3,150,000	
3 2008 28 24 Actual 1 25 3.21888 0.53 13 150,000 1,950,000 62 4 2008 29 24 Actual 2 26 3.25810 0.53 13 150,000 1,950,000 0 1 2009 30 27 Actual 3 30 3.40120 0.53 14 150,000 2,100,000 0 2 2009 31 12 Actual 4 16 2,77259 0.53 16 150,000 2,000,000 0 3 2009 32 18 Projected 0.53 10 150,000 1,500,000 0 4 2009 33 17 Projected 0.53 9 150,000 1,500,000 0 1 2010 34 15 Projected 0.53 8 150,000 1,200,000 0 2 2010 35 14 Projected 0.53 7 150,000 1,200,000 0 3 2010 36 13 Projected 0.53 7 150,000 1,500,000 0 4 2010 37 12 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 2 2011 39 10 Projected 0.53 5 150,000 750,000 0 3 2011 40 9 Projected 0.53 5 150,000 750,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 0 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 2 2012 43 7 Projected 0.53 3 150,000 450,000 0 2 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 46 5 Projected 0.53 3 150,000 300,000 0 2 2013 47 5 Projected 0.53 5 150,000 300,000 0 2 2013 48 4 Projected 0.53 5 150,000 300,000 0 2 2014 50 7 Projected 0.53 5 150,000 300,000 0 2 2015 55 2 Projected 0.53 5 150,000 300,000 0 2 2016 59 2 Projected 0.53 1 150,000 300,000 0 2 2016 59 2 Projected 0.53 1 150,000 300,000 0 2 2016 59 2 Projected 0.53 1 150,000 300,000 0 2 2016 59 2 Projected 0.53 1 150,000 300,000 0 3 2016 6			26					3.29584		14	150,000	2,100,000	
4 2008 29 24 Actual 2 26 3.25810 0.53 13 150,000 1,950,000 0 2 2009 31 12 Actual 4 16 2.77259 0.53 6 150,000 2,100,000 0 3 2009 32 18 Projected 0.53 0.53 0.150,000 1,500,000 0 4 2009 33 17 Projected 0.53 9 150,000 1,200,000 0 1 2010 34 15 Projected 0.53 7 150,000 1,200,000 0 2 2010 35 14 Projected 0.53 7 150,000 1,200,000 0 3 2010 36 13 Projected 0.53 7 150,000 1,050,000 3 4 2010 37 12 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 2 2011 39 10 Projected 0.53 6 150,000 900,000 0 2 2011 39 10 Projected 0.53 5 150,000 750,000 2 4 2011 41 8 Projected 0.53 5 150,000 750,000 2 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 5 2012 42 7 Projected 0.53 4 150,000 600,000 0 6 2012 44 6 Projected 0.53 4 150,000 600,000 0 6 2012 44 6 Projected 0.53 4 150,000 600,000 0 6 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2013 46 5 Projected 0.53 3 150,000 450,000 0 5 2013 47 5 Projected 0.53 3 150,000 450,000 0 5 2013 47 5 Projected 0.53 2 150,000 300,000 0 5 2014 50 4 Projected 0.53 2 150,000 300,000 0 6 2014 50 4 Projected 0.53 2 150,000 300,000 0 6 2014 50 4 Projected 0.53 2 150,000 300,000 0 7 2014 50 4 Projected 0.53 2 150,000 300,000 0 7 2014 50 4 Projected 0.53 2 150,000 300,000 0 8 2014 52 3 Projected 0.53 2 150,000 300,000 0 9 2016 69 2 Projected 0.53 1 150,000 150,000 0 1 2016 68 4 Projected 0.53 1 150,000 150,000 0 1 2016 68 4 Projected 0.53 1 150,0													
1 2009 30 27 Actual 3 30 3.40120 0.53 14 150,000 2.100,000 0													
2 2009 31 12 Actual 4 16 2.77259 0.53 6 150,000 900,000 0 3 2009 32 18 Projected 0.53 9 150,000 1,350,000 43 4 2009 33 17 Projected 0.53 9 150,000 1,350,000 0 1 2010 34 15 Projected 0.53 7 150,000 1,200,000 0 2 2010 35 14 Projected 0.53 7 150,000 1,050,000 0 3 2010 36 13 Projected 0.53 7 150,000 1,050,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 2 2011 39 10 Projected 0.53 6 150,000 900,000 0 2 2011 40 9 Projected 0.53 5 150,000 900,000 0 3 2011 40 8 Projected 0.53 5 150,000 750,000 22 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 6 Projected 0.53 4 150,000 600,000 0 2 2012 45 6 Projected 0.53 3 150,000 450,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 0 2 2013 47 6 Projected 0.53 3 150,000 450,000 0 2 2013 47 6 Projected 0.53 3 150,000 450,000 0 2 2013 47 6 Projected 0.53 3 150,000 450,000 0 2 2013 47 6 Projected 0.53 3 150,000 450,000 0 2 2013 49 4 Projected 0.53 3 150,000 450,000 0 3 2014 50 4 Projected 0.53 3 150,000 300,000 0 4 2013 49 4 Projected 0.53 3 150,000 300,000 0 5 2013 57 5 5 8 Projected 0.53 3 150,000 300,000 0 5 2013 57 5 8 Projected 0.53 3 150,000 300,000 0 5 2014 50 4 Projected 0.53 2 150,000 300,000 0 5 2014 50 4 Projected 0.53 2 150,000 300,000 0 6 2 2013 57 6 Projected 0.53 1 150,000 150,000 0 6 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 6 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 6 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 6 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 7 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 7 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 7 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 7 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 7 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 7 3 2018 68 1 Projected 0.53 1 150,000 150,000 0 7 3 2018 68 1 Projected 0.53 1 150,000 150,000 0 7 3 2018 68 1 Projected 0.53 1 150,000 150,000 0 7 3 2018													
3 2009 32 18 Projected 0.53 10 150,000 1,500,000 43 4 2009 33 17 Projected 0.53 9 150,000 1,250,000 0 1 2010 34 15 Projected 0.53 8 150,000 1,250,000 0 0 2 2010 35 14 Projected 0.53 7 150,000 1,050,000 0 0 0 0 0 0 0 0													
4 2009 33 17 Projected 0.53 8 150,000 1,350,000 0 1 2010 34 15 Projected 0.53 8 150,000 1,200,000 0 2 2010 35 14 Projected 0.53 7 150,000 1,050,000 0 3 2010 36 13 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 2 2011 39 10 Projected 0.53 5 150,000 750,000 0 3 2011 40 9 Projected 0.53 5 150,000 750,000 0 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 3 150,000 450,000 0						4	16	2.77259					
1 2010 34 15 Projected 0.53 7 150,000 1,200,000 0 2 2010 35 14 Projected 0.53 7 150,000 1,050,000 0 3 2010 36 13 Projected 0.53 7 150,000 1,050,000 31 4 2010 37 12 Projected 0.53 7 150,000 900,000 0 1 2010 37 12 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 0 2 2011 39 10 Projected 0.53 5 150,000 750,000 0 2 2011 40 9 Projected 0.53 5 150,000 750,000 0 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 0 1 2012 44 6 Projected 0.53 4 150,000 450,000 0 0 1 2 2012 45 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 0 2 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 0 2 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 0 1 2 2013 48 4 Projected 0.53 3 150,000 450,000 0 0 1 2 2013 48 4 Projected 0.53 3 150,000 450,000 0 0 1 2 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 0 1 2 2 2013 47 5 Projected 0.53 2 150,000 300,000 0 1 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 1 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 1 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 0 2 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 2 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 1 2 2014 53 3 Projected 0.53 2 150,000 300,000 0 0 1 2 2015 55 2 Projected 0.53 1 150,000 300,000 0 0 1 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 58 2 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 1 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 2 2016 60 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2016 60 1 Projected 0.53 1 150,00													
2 2010 35 14 Projected 0.53 7 150,000 1,050,000 3 3 2010 36 13 Projected 0.53 7 150,000 1,050,000 31 4 2010 37 12 Projected 0.53 6 150,000 900,000 0 2 2011 38 11 Projected 0.53 5 150,000 750,000 0 3 2011 40 9 Projected 0.53 5 150,000 750,000 22 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 0 4 2012 45 6 Projected 0.53 3 150,000 450,000 0													
3 2010 36 13 Projected 0.53 7 150,000 1,050,000 31 4 2010 37 12 Projected 0.53 6 150,000 900,000 0 0 1 2011 38 11 Projected 0.53 6 150,000 900,000 0 0 0 0 0 0 0 0													
4 2010 37 12 Projected 0.53 6 150,000 900,000 0 1 2011 38 11 Projected 0.53 6 150,000 750,000 0 3 2011 40 9 Projected 0.53 5 150,000 750,000 0 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 47 5 Projected 0.53 3 150,000 300,000 0 2 2013 47													
1 2011 38 11 Projected 0.53 6 150,000 750,000 0 2 2011 39 10 Projected 0.53 5 150,000 750,000 22 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2012 44 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 2 150,000 300,000 1 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>													
2 2011 39 10 Projected 0.53 5 150,000 750,000 22 4 2011 40 9 Projected 0.53 5 150,000 750,000 22 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 47 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 300,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 1 2014 50													
3 2011 40 9 Projected 0.53 5 150,000 750,000 22 4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 0 3 2012 45 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 0 2 2013 48 4 Projected 0.53 3 150,000 450,000 0 0 3 2013 48 4 Projected 0.53 3 150,000 450,000 0 0 1 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 0 1 2014 53 3 Projected 0.53 2 150,000 300,000 0 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 0 2 2015 54 3 Projected 0.53 2 150,000 300,000 0 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 0 1 2015 54 3 Projected 0.53 1 150,000 300,000 0 0 1 2015 55 2 Projected 0.53 1 150,000 150,000 0 0 1 2015 56 2 Projected 0.53 1 150,000 150,000 0 0 1 2015 56 2 Projected 0.53 1 150,000 150,000 0 0 1 2016 59 2 Projected 0.53 1 150,000 150,000 0 0 1 2016 59 2 Projected 0.53 1 150,000 150,000 0 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2017 65 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 0 1 1 2018 66 1 Projected 0.5													
4 2011 41 8 Projected 0.53 4 150,000 600,000 0 1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 50 4 Projected 0.53 2 150,000 300,000 0 2<													
1 2012 42 7 Projected 0.53 4 150,000 600,000 0 2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 0 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 48 4 Projected 0.53 3 150,000 300,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 1 2013 49 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 </td <td></td>													
2 2012 43 7 Projected 0.53 4 150,000 600,000 0 3 2012 44 6 Projected 0.53 3 150,000 450,000 0 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 300,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 </td <td></td>													
3 2012 44 6 Projected 0.53 3 150,000 450,000 15 4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 6 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1<													
4 2012 45 6 Projected 0.53 3 150,000 450,000 0 1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 300,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 1 150,000 150,000 0 2 </td <td></td>													
1 2013 46 5 Projected 0.53 3 150,000 450,000 0 2 2013 47 5 Projected 0.53 3 150,000 450,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 11 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3<													
2 2013 47 5 Projected 0.53 3 150,000 450,000 0 3 2013 48 4 Projected 0.53 2 150,000 300,000 0 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 <td></td>													
3 2013 48 4 Projected 0.53 2 150,000 300,000 11 4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 2 150,000 300,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 <td></td>													
4 2013 49 4 Projected 0.53 2 150,000 300,000 0 1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 2 </td <td></td>													
1 2014 50 4 Projected 0.53 2 150,000 300,000 0 2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 53 3 Projected 0.53 2 150,000 300,000 0 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 1 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 2 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 <td></td>													
2 2014 51 3 Projected 0.53 2 150,000 300,000 0 3 2014 52 3 Projected 0.53 2 150,000 300,000 8 4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 0 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 <td>1</td> <td>2014</td> <td>50</td> <td>4 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1	2014	50	4 P	rojected								
4 2014 53 3 Projected 0.53 2 150,000 300,000 0 1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 6 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 2 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 </td <td>2</td> <td>2014</td> <td>51</td> <td>3 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td>0.53</td> <td>2</td> <td>150,000</td> <td>300,000</td> <td>0</td>	2	2014	51	3 P	rojected				0.53	2	150,000	300,000	0
1 2015 54 3 Projected 0.53 2 150,000 300,000 0 2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 6 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 4 2016 61 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 0 <td>3</td> <td></td> <td></td> <td>3 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>300,000</td> <td></td>	3			3 P	rojected							300,000	
2 2015 55 2 Projected 0.53 1 150,000 150,000 0 3 2015 56 2 Projected 0.53 1 150,000 150,000 6 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 0 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 0 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 <td>4</td> <td>2014</td> <td>53</td> <td>3 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td>0.53</td> <td>2</td> <td>150,000</td> <td>300,000</td> <td>0</td>	4	2014	53	3 P	rojected				0.53	2	150,000	300,000	0
3 2015 56 2 Projected 0.53 1 150,000 150,000 6 4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 0 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 3 </td <td>1</td> <td>2015</td> <td>54</td> <td>3 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td>0.53</td> <td>2</td> <td>150,000</td> <td>300,000</td> <td>0</td>	1	2015	54	3 P	rojected				0.53	2	150,000	300,000	0
4 2015 57 2 Projected 0.53 1 150,000 150,000 0 1 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 0 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 <td>2</td> <td>2015</td> <td>55</td> <td>2 P</td> <td>rojected</td> <td></td> <td></td> <td></td> <td>0.53</td> <td>1</td> <td>150,000</td> <td>150,000</td> <td>0</td>	2	2015	55	2 P	rojected				0.53	1	150,000	150,000	0
1 2016 58 2 Projected 0.53 1 150,000 150,000 0 2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 65 1 Projected 0.53 1 150,000 150,000 4 4 2018 66 1 Projected 0.53 1 150,000 150,000 0 1 2018 67 1 Projected 0.53 1 150,000 150,000 0 2 2018 68 1 Projected 0.53 1 150,000 150,000 0 4 2018 69 1 Projected 0.53 1 150,000 150,000 0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td>										1			
2 2016 59 2 Projected 0.53 1 150,000 150,000 0 3 2016 60 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 0 4 2018 69 1 Projected 0.53 1 150,000 150,000 0 <td></td>													
3 2016 60 1 Projected 0.53 1 150,000 150,000 4 4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
4 2016 61 1 Projected 0.53 1 150,000 150,000 0 1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 4 4 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
1 2017 62 1 Projected 0.53 1 150,000 150,000 0 2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
2 2017 63 1 Projected 0.53 1 150,000 150,000 0 3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
3 2017 64 1 Projected 0.53 1 150,000 150,000 4 4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
4 2017 65 1 Projected 0.53 1 150,000 150,000 0 1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
1 2018 66 1 Projected 0.53 1 150,000 150,000 0 2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
2 2018 67 1 Projected 0.53 1 150,000 150,000 0 3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
3 2018 68 1 Projected 0.53 1 150,000 150,000 4 4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
4 2018 69 1 Projected 0.53 1 150,000 150,000 0													
. 2010 /V 1110jested 0.00 1 100,000 100,000 0													
	•	_0.0	, ,		. 5,0000				0.00		.00,000	700,000	· ·

PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM DISEASE CASES

Exhibit 4

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
						- (0) 1 (0)		Selected	-(i) x (o)		Estimated	Approved Cases By
Quarter			Number of		Judgmental			Approval	Approved	Case	Ultimate	Fiscal
Filed	Year	t	Cases		Adjustment	у	ln(y)	Rate	Cases	Amount	Compensation	Year
2	2019	71	1	Projected				0.53	1	150,000	150,000	0
3	2019	72	1	Projected				0.53	1	150,000	150,000	4
4	2019	73	0	Projected				0.53	0	150,000	0	0
1	2020	74	0	Projected				0.53	0	150,000	0	0
2	2020	75	0	Projected				0.53	0	150,000	0	0
3	2020	76	0	Projected				0.53	0	150,000	0	0
4	2020	77	0	Projected				0.53	0	150,000	0	0
1	2021	78	0	Projected				0.53	0	150,000	0	0
2	2021	79	0	Projected				0.53	0	150,000	0	0
3	2021	80	0	Projected				0.53	0	150,000	0	0
4	2021	81	0	Projected				0.53	0	150,000	0	0
1	2022	82	0	Projected				0.53	0	150,000	0	0
2	2022	83	0	Projected				0.53	0	150,000	0	0
3	2022	84	0	Projected				0.53	0	150,000	0	0
4	2022	85		Projected				0.53	0	150,000	0	0
1	2023	86	0	Projected				0.53	0	150,000	0	0
2	2023	87		Projected				0.53	0	150,000	0	0
3	2023	88		Projected				0.53	0	150,000	0	0
4	2023	89		Projected				0.53	0	150,000	0	0
1	2024	90		Projected				0.53	0	150,000	0	0
2	2024	91		Projected				0.53	0	150,000	0	0
3	2024	92		Projected				0.53	0	150,000	0	0
4	2024	93		Projected				0.53	0	150,000	0	0
1	2025	94		Projected				0.53	0	150,000	0	0
2	2025	95		Projected				0.53	Ö	150,000	0	Ö
3	2025	96		Projected				0.53	0	150,000	0	0
4	2025	97		Projected				0.53	0	150,000	0	0
1	2026	98		Projected				0.53	0	150,000	0	0
2	2026	99		Projected				0.53	0	150,000	0	0
3	2026	100		Projected				0.53	0	150,000	0	0
4	2026	101		Projected				0.53	0	150,000	0	0
1	2027	102		Projected				0.53	0	150,000	0	0
2	2027	103		Projected				0.53	0	150,000	0	0
3	2027	104		Projected				0.53	0	150,000	0	0
4	2027	105		Projected				0.53	0	150,000	0	0
1	2028	106		Projected				0.53	0	150,000	0	0
2	2028	107		Projected				0.53	0	150,000	0	0
3	2028	108		Projected				0.53	0	150,000	0	0
4	2028	109		Projected				0.53	0	150,000	0	0
1	2029	110		Projected				0.53	0	150,000	0	0
2	2029	111		Projected				0.53	0	150,000	0	0
3	2029	112		Projected				0.53	Ō	150,000	0	Ö
4	2029	113		Projected				0.53	0	150,000	0	Ō
1	2030	114		Projected				0.53	0	150,000	0	0
2	2030	115		Projected				0.53	0	150,000	0	Ō
3	2030	116		Projected				0.53	0	150,000	0	Ō
				•								
			4,331						2,301		345,150,000	2,301
			,,,,,						,-,-		-,,	,

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

Parameters for fitted curve m -0.0404 3.0677 b Starting 3Q 2004 m -0.0361 3.0156 b Parameters Selected for m -0.0404 3.0677 b

CASES BY QUARTER

	(1)	(2)	(3)	4) (5)	(6) = (3) + (5)	(7)	-8.00	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
							Selected			Estimated	Approved Cases By
Quarter	Voor		Number of	Judgmental	.,	ln/v)	Approval	Approved	Case	Ultimate	Fiscal
Filed 3	Year 2001	t	Cases 123 Actua	Adjustment al	y 0 123	ln(y) 4.81218	Rate 0.18	Cases 22	Amount 150,000	Compensation 3,300,000	Year 22
4	2001	1	75 Actua	al	0 75	4.31749	0.18	14	150,000	2,100,000	0
1	2002	2	43 Actua		0 43	3.76120	0.18	8	150,000	1,200,000	0
2 3	2002 2002	3 4	20 Actua 17 Actua		0 20 0 17	2.99573 2.83321	0.18 0.18	4	150,000 150,000	600,000 450,000	0 29
4	2002	5	17 Actua		0 17	2.83321	0.18	3	150,000	450,000	0
1	2003	6	6 Actua		0 6	1.79176	0.18	1	150,000	150,000	0
2 3	2003 2003	7 8	11 Actua 13 Actua		0 11 0 13	2.39790 2.56495	0.18 0.18	2	150,000 150,000	300,000 300,000	0 8
4	2003	9	9 Actua		0 9	2.19722	0.18	2	150,000	300,000	0
1	2004	10	14 Actua	al	0 14	2.63906	0.18	3	150,000	450,000	0
2	2004	11	7 Actua		0 7	1.94591	0.18	1	150,000	150,000	0
3 4	2004 2004	12 13	21 Actua 14 Actua		0 21 0 14	3.04452 2.63906	0.18 0.18	4	150,000 150,000	600,000 450,000	10 0
1	2005	14	14 Actua		0 14	2.63906	0.18	3	150,000	450,000	0
2	2005	15	13 Actua		0 13	2.56495	0.18	2	150,000	300,000	0
3	2005	16 17	9 Actua		0 9 8	2.19722	0.18	2 1	150,000	300,000	10
4 1	2005 2006	17	8 Actua 10 Actua		0 10	2.07944 2.30259	0.18 0.18	2	150,000 150,000	150,000 300,000	0
2	2006	19	5 Actua		0 5	1.60944	0.18	1	150,000	150,000	0
3	2006	20	8 Actua		8 0	2.07944	0.18	1	150,000	150,000	5
4 1	2006 2007	21 22	17 Actua 9 Actua		0 17 0 9	2.83321 2.19722	0.18 0.18	3 2	150,000 150,000	450,000 300,000	0
2	2007	23	7 Actua		0 7	1.94591	0.18	1	150,000	150,000	0
3	2007	24	9 Actua	al	0 9	2.19722	0.18	2	150,000	300,000	8
4	2007	25	14 Actua		0 14	2.63906	0.18	3	150,000	450,000	0
1 2	2008 2008	26 27	6 Actua 6 Actua		0 6	1.79176 1.79176	0.18 0.18	1	150,000 150,000	150,000 150,000	0
3	2008	28	10 Actua		1 11	2.39790	0.18	2	150,000	300,000	7
4	2008	29	5 Actua		2 7	1.94591	0.18	1	150,000	150,000	0
1	2009	30	4 Actua		3 7 4 7	1.94591	0.18	1	150,000	150,000	0
2	2009 2009	31 32	3 Actua 6 Proje		4 /	1.94591	0.18 0.18	1	150,000 150,000	150,000 150,000	0 4
4	2009	33	6 Proje				0.18	1	150,000	150,000	0
1	2010	34	5 Proje				0.18	1	150,000	150,000	0
2 3	2010 2010	35 36	5 Proje 5 Proje				0.18 0.18	1	150,000 150,000	150,000 150,000	0 4
4	2010	37	5 Proje				0.18	i	150,000	150,000	0
1	2011	38	5 Proje				0.18	1	150,000	150,000	0
2	2011	39	4 Proje				0.18	1	150,000	150,000	0
3 4	2011 2011	40 41	4 Proje 4 Proje				0.18 0.18	1	150,000 150,000	150,000 150,000	4 0
1	2012	42	4 Proje				0.18	1	150,000	150,000	0
2	2012	43	4 Proje				0.18	1	150,000	150,000	0
3 4	2012 2012	44 45	4 Proje 3 Proje				0.18 0.18	1	150,000 150,000	150,000 150,000	4 0
1	2012	46	3 Proje				0.18	1	150,000	150,000	0
2	2013	47	3 Proje	cted			0.18	1	150,000	150,000	0
3	2013	48	3 Proje				0.18	1	150,000	150,000	4
4 1	2013 2014	49 50	3 Proje 3 Proje				0.18 0.18	1	150,000 150,000	150,000 150,000	0
2	2014	51	3 Proje				0.18	1	150,000	150,000	0
3	2014	52	3 Proje				0.18	1	150,000	150,000	4
4 1	2014 2015	53 54	3 Proje 2 Proje				0.18 0.18	1	150,000 150,000	150,000 0	0
2	2015	55	2 Proje				0.18	0	150,000	0	0
3	2015	56	2 Proje	cted			0.18	0	150,000	0	1
4	2015	57	2 Proje				0.18	0	150,000	0	0
1 2	2016 2016	58 59	2 Proje 2 Proje				0.18 0.18	0	150,000 150,000	0	0 0
3	2016	60	2 Proje	cted			0.18	0	150,000	0	0
4	2016	61	2 Proje				0.18	0	150,000	0	0
1 2	2017 2017	62 63	2 Proje 2 Proje				0.18 0.18	0	150,000 150,000	0	0 0
3	2017	64	2 Proje 2 Proje				0.18	0	150,000	0	0
4	2017	65	2 Proje	cted			0.18	0	150,000	0	0
1	2018	66	1 Proje				0.18	0	150,000	0	0
2 3	2018 2018	67 68	1 Proje 1 Proje				0.18 0.18	0	150,000 150,000	0	0 0
4	2018	69	1 Proje				0.18	0	150,000	0	0
1	2019	70	1 Proje				0.18	0	150,000	0	0

PROJECTED APPROVED CASES BY QUARTER FILED FOR CHRONIC SILICOSIS CASES

Exhibit 4

CASES BY QUARTER

Quarter Filed Vear 1 Cases Number of Judgmental Year 1 Cases Adjustment Year 1 Cases Number of Judgmental Year Number of Judgmental Year Number of Judgmental Year Number of Selected Number of Number of Number of Judgmental Year Number of Number of		(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	-8.00	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Filed Year													Cases By
2 2019 71 1 Projected													
3 2019 72 1 Projected						Adjustment	у	ln(y)					
4 2019 73 Projected 0.18													
1 2020 74 1 Projected													
2 2020 75 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0													
3 2020 76													
1													
1 2021 78													
2 2021 79													
3 2021 80					•								
4 2021 81 1 Projected													
1 2022 82 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					•								
2 2022 83 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
3 2022 84 1 Projected 0.18 0 150,000 0 0 0 1 2023 85 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
4 2022 85 1 Projected 0.18 0 150,000 0 0 0 1 2023 86 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
1 2023 86 1 Projected 0.18 0 150,000 0 0 2 2023 87 1 Projected 0.18 0 150,000 0 0 3 2023 88 1 Projected 0.18 0 150,000 0 0 4 2023 89 1 Projected 0.18 0 150,000 0 0 1 2024 90 1 Projected 0.18 0 150,000 0 0 2 2024 91 1 Projected 0.18 0 150,000 0 0 3 2024 92 1 Projected 0.18 0 150,000 0 0 4 2024 93 1 Projected 0.18 0 150,000 0 0 1 2025 94 0 Projected 0.18 0 150,000 0 0 2 2025 96 0 Projected 0.18 0 150,000 0 0 3 2025 96 0													
2 2023 87 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
3 2023 88 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
4 2023 89 1 Projected 0.18 0 150,000 0 0 0 1 2024 90 1 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
1 2024 90 1 Projected 0.18 0 150,000 0 0 2 2024 91 1 Projected 0.18 0 150,000 0 0 3 2024 92 1 Projected 0.18 0 150,000 0 0 4 2024 93 1 Projected 0.18 0 150,000 0 0 1 2025 94 0 Projected 0.18 0 150,000 0 0 2 2025 96 0 Projected 0.18 0 150,000 0 0 3 2025 96 0 Projected 0.18 0 150,000 0 0 4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0					•								
2 2024 91 1 Projected 0.18 0 150,000 0 0 3 2024 92 1 Projected 0.18 0 150,000 0 0 4 2024 93 1 Projected 0.18 0 150,000 0 0 1 2025 94 0 Projected 0.18 0 150,000 0 0 2 2025 95 0 Projected 0.18 0 150,000 0 0 3 2025 96 0 Projected 0.18 0 150,000 0 0 4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2026													
3 2024 92 1 Projected					•								
4 2024 93 1 Projected 0.18 0 150,000 0 0 1 2025 94 0 Projected 0.18 0 150,000 0 0 2 2025 95 0 Projected 0.18 0 150,000 0 0 3 2025 96 0 Projected 0.18 0 150,000 0 0 4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 4 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
1 2025 94 0 Projected 0.18 0 150,000 0 0 2 2025 95 0 Projected 0.18 0 150,000 0 0 4 2025 96 0 Projected 0.18 0 150,000 0 0 4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 <					•								
2 2025 95 0 Projected 0.18 0 150,000 0 0 3 2025 96 0 Projected 0.18 0 150,000 0 0 4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 4 2028 106													
3 2025 96 0 Projected 0.18 0 150,000 0 0 0 0 0 1 2026 97 0 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0													
4 2025 97 0 Projected 0.18 0 150,000 0 0 1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106													
1 2026 98 0 Projected 0.18 0 150,000 0 0 2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028					•								
2 2026 99 0 Projected 0.18 0 150,000 0 0 3 2026 100 0 Projected 0.18 0 150,000 0 0 4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 105 0 Projected 0.18 0 150,000 0 0 4 2028 106 0 Projected 0.18 0 150,000 0 0 1 2028 107 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 <td></td>													
3 2026 100 0 Projected 0.18 0 150,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					•								
4 2026 101 0 Projected 0.18 0 150,000 0 0 1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 <td></td>													
1 2027 102 0 Projected 0.18 0 150,000 0 0 2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 <td></td> <td></td> <td></td> <td></td> <td>•</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>					•								
2 2027 103 0 Projected 0.18 0 150,000 0 0 3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 <td></td>													
3 2027 104 0 Projected 0.18 0 150,000 0 0 4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 <td></td> <td>,</td> <td></td> <td></td>											,		
4 2027 105 0 Projected 0.18 0 150,000 0 0 1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 <td></td>													
1 2028 106 0 Projected 0.18 0 150,000 0 0 2 2028 107 0 Projected 0.18 0 150,000 0 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0					•								
2 2028 107 0 Projected 0.18 0 150,000 0 0 3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0													
3 2028 108 0 Projected 0.18 0 150,000 0 0 4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0					•								
4 2028 109 0 Projected 0.18 0 150,000 0 0 1 2029 110 0 Projected 0.18 0 150,000 0 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0			108							0			
1 2029 110 0 Projected 0.18 0 150,000 0 0 2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0					•								
2 2029 111 0 Projected 0.18 0 150,000 0 0 3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0										0			
3 2029 112 0 Projected 0.18 0 150,000 0 0 4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0					•					0			
4 2029 113 0 Projected 0.18 0 150,000 0 0 1 2030 114 0 Projected 0.18 0 150,000 0 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0													
1 2030 114 0 Projected 0.18 0 150,000 0 2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0													
2 2030 115 0 Projected 0.18 0 150,000 0 0 3 2030 116 0 Projected 0.18 0 150,000 0 0 0	1	2030	114						0.18	0	150,000	0	0
3 2030 116 0 Projected 0.18 0 150,000 0 0	2	2030	115						0.18	0		0	0
687 124 18,600,000 124	3	2030	116	0	Projected				0.18	0	150,000	0	0
687 124 18,600,000 124													
687 124 18,600,000 124													
				687						124		18,600,000	124

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER SEC CASES

Exhibit 4

Parameters for fitted curve m -0.0205 6.4646 b Starting 3Q 2004 m 0.0056 5.8742 b Parameters Selected for m -0.0225 6.6000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter			Number of		Judgmental			Selected Approval	Approved	Case	Estimated Ultimate	Approved Cases By Fiscal
Filed	Year	t	Cases		Adjustment	у	In(y)	Rate	Cases	Amount	Compensation	Year
3	2001		2,364 A			2364	7.76811	0.77	1820	150,000	273,000,000	1,820
4	2001	1	1,055 A		C		6.96130	0.77	812	150,000	121,800,000	0
1 2	2002 2002	2	1,123 A 803 A		0		7.02376 6.68835	0.77 0.77	865 618	150,000 150,000	129,750,000 92,700,000	0
3	2002	4	714 A		0		6.57088	0.77	550	150,000	82,500,000	2,845
4	2002	5	488 A		Ċ		6.19032	0.77	376	150,000	56,400,000	0
1	2003	6	530 A		C		6.27288	0.77	408	150,000	61,200,000	0
2	2003 2003	7 8	473 A 417 A		0		6.15910 6.03309	0.77 0.77	364 321	150,000 150,000	54,600,000	0 1,469
4	2003	9	433 A		0		6.07074	0.77	333	150,000	48,150,000 49,950,000	0
1	2004	10	552 A		ď		6.31355	0.77	425	150,000	63,750,000	0
2	2004	11	437 A		C		6.07993	0.77	336	150,000	50,400,000	0
3 4	2004 2004	12 13	524 A 373 A		0		6.26149 5.92158	0.77 0.77	403 287	150,000 150,000	60,450,000 43,050,000	1,497 0
1	2004	14	418 A		0		6.03548	0.77	322	150,000	48,300,000	0
2	2005	15	437 A		Ċ		6.07993	0.77	336	150,000	50,400,000	0
3	2005	16	334 A		C		5.81114	0.77	257	150,000	38,550,000	1,202
4	2005	17	368 A		0		5.90808	0.77	283	150,000	42,450,000	0
2	2006 2006	18 19	355 A 347 A		(5.87212 5.84932	0.77 0.77	273 267	150,000 150,000	40,950,000 40,050,000	0
3	2006	20	320 A		Č		5.76832	0.77	246	150,000	36,900,000	1,069
4	2006	21	358 A		C		5.88053	0.77	276	150,000	41,400,000	0
1	2007	22	426 A		C		6.05444	0.77	328	150,000	49,200,000	0
2	2007 2007	23 24	360 A 389 A		0		5.88610 5.96358	0.77 0.77	277 300	150,000 150,000	41,550,000 45,000,000	0 1,181
4	2007	25	400 A		C		5.99146	0.77	308	150,000	46,200,000	0
1	2008	26	388 A	Actual	C		5.96101	0.77	299	150,000	44,850,000	0
2	2008	27	495 A		C		6.20456	0.77	381	150,000	57,150,000	0
3 4	2008 2008	28 29	549 A 412 A		1		6.30992 6.02587	0.77 0.77	423 317	150,000 150,000	63,450,000 47,550,000	1,411 0
1	2009	30	477 A		3		6.17379	0.77	367	150,000	55,050,000	0
2	2009	31	369 A		4		5.92158	0.77	284	150,000	42,600,000	0
3	2009	32		Projected				0.77	276	150,000	41,400,000	1,244
4 1	2009 2010	33 34		Projected Projected				0.77 0.77	270 263	150,000 150,000	40,500,000 39,450,000	0
2	2010	35		Projected				0.77	257	150,000	38,550,000	0
3	2010	36		Projected				0.77	252	150,000	37,800,000	1,042
4	2010	37		Projected				0.77	246	150,000	36,900,000	0
1 2	2011 2011	38 39		Projected Projected				0.77 0.77	241 236	150,000 150,000	36,150,000 35,400,000	0
3	2011	40		rojected				0.77	230	150,000	34,500,000	953
4	2011	41		Projected				0.77	225	150,000	33,750,000	0
1	2012	42		Projected				0.77	220	150,000	33,000,000	0
2	2012 2012	43 44		Projected Projected				0.77 0.77	215 210	150,000 150,000	32,250,000 31,500,000	0 870
4	2012	45		Projected				0.77	206	150,000	30,900,000	0
1	2013	46		Projected				0.77	201	150,000	30,150,000	0
2	2013 2013	47 48		Projected Projected				0.77 0.77	196 193	150,000 150,000	29,400,000 28,950,000	0 796
4	2013	49		Projected				0.77	188	150,000	28,200,000	0
1	2014	50		rojected				0.77	184	150,000	27,600,000	0
2	2014	51		Projected				0.77	179	150,000	26,850,000	0
3 4	2014 2014	52 53		Projected Projected				0.77 0.77	176 172	150,000 150,000	26,400,000 25,800,000	727 0
1	2014	54		Projected				0.77	168	150,000	25,200,000	0
2	2015	55		Projected				0.77	164	150,000	24,600,000	0
3	2015	56		rojected				0.77	161	150,000	24,150,000	665
4	2015 2016	57 58		Projected Projected				0.77 0.77	157 153	150,000 150,000	23,550,000 22,950,000	0
2	2016	59		Projected				0.77	150	150,000	22,500,000	0
3	2016	60		rojected				0.77	147	150,000	22,050,000	607
4	2016	61		Projected				0.77	143	150,000	21,450,000	0
1 2	2017 2017	62 63		Projected Projected				0.77 0.77	140 137	150,000 150,000	21,000,000 20,550,000	0
3	2017	64		Projected				0.77	134	150,000	20,100,000	554
4	2017	65	170 P	Projected				0.77	131	150,000	19,650,000	0
1	2018	66		Projected				0.77	129	150,000	19,350,000	0
2	2018 2018	67 68		Projected Projected				0.77 0.77	126 122	150,000 150,000	18,900,000 18,300,000	0 508
4	2018	69		Projected				0.77	120	150,000	18,000,000	0
1	2019	70	152 F	Projected				0.77	117	150,000	17,550,000	0
2	2019	71 72		Projected Projected				0.77	115	150,000	17,250,000	0
3	2019	72	145 P	rojected				0.77	112	150,000	16,800,000	464

PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER SEC CASES

Exhibit 4

Parameters for fitted curve m -0.0205 6.4646 b Starting 3Q 2004 m 0.0056 5.8742 b Parameters Selected for m -0.0225 6.6000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
						(-) - (-)			() (-)		(-)	Approved
								Selected			Estimated	Cases By
Quarter			Number of		Judgmental			Approval	Approved	Case	Ultimate	Fiscal
Filed	Year	t	Cases		Adjustment	у	In(y)	Rate	Cases	Amount	Compensation	Year
4	2019	73	142	Projected				0.77	109	150,000	16,350,000	0
1	2020	74	139	Projected				0.77	107	150,000	16,050,000	0
2	2020	75		Projected				0.77	105	150,000	15,750,000	0
3	2020	76		Projected				0.77	102	150,000	15,300,000	423
4	2020	77		Projected				0.77	100	150,000	15,000,000	0
1	2021	78		Projected				0.77	98	150,000	14,700,000	0
2	2021	79		Projected				0.77	95	150,000	14,250,000	0
3	2021	80		Projected				0.77	94	150,000	14,100,000	387
4	2021	81		Projected				0.77	92	150,000	13,800,000	0
1	2022	82		Projected				0.77	89	150,000	13,350,000	0
2	2022	83		Projected				0.77	88	150,000	13,200,000	0
3	2022	84		Projected				0.77	85	150,000	12,750,000	354
4	2022	85		Projected				0.77	84	150,000	12,600,000	0
1	2023	86		Projected				0.77	82	150,000	12,300,000	0
2	2023	87		Projected				0.77	80	150,000	12,000,000	0
3	2023	88		Projected				0.77	78	150,000	11,700,000	324
4	2023	89		Projected				0.77	76	150,000	11,400,000	0
1	2024	90		Projected				0.77	75	150,000	11,250,000	0
2	2024	91		Projected				0.77	73	150,000	10,950,000	0
3	2024	92		Projected				0.77	72	150,000	10,800,000	296
4	2024	93		Projected				0.77	70	150,000	10,500,000	0
1	2025	94		Projected				0.77	69	150,000	10,350,000	0
2	2025	95		Projected				0.77	67	150,000	10,050,000	0
3	2025	96		Projected				0.77	65	150,000	9,750,000	271
4	2025	97		Projected				0.77	64	150,000	9,600,000	0
1	2026	98		Projected				0.77	62	150,000	9,300,000	0
2	2026	99		Projected				0.77	61	150,000	9,150,000	0
3 4	2026	100		Projected				0.77 0.77	59	150,000	8,850,000	246
1	2026 2027	101 102		Projected				0.77	59 57	150,000	8,850,000	0
2	2027	102		Projected				0.77	57 55	150,000	8,550,000	0
3	2027	103		Projected Projected				0.77	55 55	150,000 150,000	8,250,000 8,250,000	226
4	2027	104		Projected				0.77	53	150,000	7,950,000	0
1	2028	105		Projected				0.77	52	150,000	7,800,000	0
2	2028	107		Projected				0.77	51	150,000	7,650,000	0
3	2028	107		Projected				0.77	50	150,000	7,500,000	206
4	2028	109		Projected				0.77	49	150,000	7,350,000	0
1	2029	110		Projected				0.77	48	150,000	7,200,000	0
2	2029	111		Projected				0.77	46	150,000	6,900,000	0
3	2029	112		Projected				0.77	45	150,000	6,750,000	188
4	2029	113		Projected				0.77	45	150,000	6,750,000	0
1	2030	114		Projected				0.77	44	150,000	6,600,000	0
2	2030	115		Projected				0.77	42	150,000	6,300,000	0
3	2030	116		Projected				0.77	42	150,000	6,300,000	173
3	2000		34	ojoolau				0.77	-12	700,000	0,000,000	175
			31,195						24,018		3,602,700,000	24,018
			31,195						24,010		5,502,700,000	24,010

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER NON SEC CASES

Parameters for fitted curve m -0.0506 7.2373 b Starting 3Q 2004 m -0.0337 6.8631 b Parameters Selected for m -0.0450 7.2500 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	-8.00	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
												Approved
Ouerter			Number of		ludamental			Selected	Annroyad	Cooo	Estimated	Cases By
Quarter Filed	Year	t	Number of Cases		Judgmental Adjustment	у	In(y)	Approval Rate	Approved Cases	Case Amount	Ultimate Compensation	Fiscal Year
3	2001			Actual	rajustinoni (8.17555	0.26	924	150,000	138,600,000	924
4	2001	1		Actual	(7.95437	0.26	740	150,000	111,000,000	0
1	2002	2		Actual	(7.72930	0.26	591	150,000	88,650,000	0
2	2002	3		Actual	(7.23418	0.26	360	150,000	54,000,000	0
3 4	2002 2002	4 5		Actual Actual	(6.90274 6.66313	0.26 0.26	259 204	150,000 150,000	38,850,000 30,600,000	1,950 0
1	2003	6		Actual	Č		6.72503	0.26	217	150,000	32,550,000	0
2	2003	7		Actual	Ċ		6.72863	0.26	217	150,000	32,550,000	0
3	2003	8		Actual	(6.63595	0.26	198	150,000	29,700,000	836
4	2003	9		Actual	(6.65157	0.26	201	150,000	30,150,000	0
1 2	2004 2004	10 11		Actual Actual	(6.76273 6.50728	0.26 0.26	225 174	150,000 150,000	33,750,000 26,100,000	0
3	2004	12		Actual	(6.62539	0.26	196	150,000	29,400,000	796
4	2004	13		Actual	Ċ		6.22456	0.26	131	150,000	19,650,000	0
1	2005	14	698	Actual	(698	6.54822	0.26	181	150,000	27,150,000	0
2	2005	15		Actual	(6.50877	0.26	174	150,000	26,100,000	0
3 4	2005	16 17		Actual	(6.38519	0.26	154	150,000	23,100,000	640
1	2005 2006	18		Actual Actual	(6.07535 6.12905	0.26 0.26	113 119	150,000 150,000	16,950,000 17,850,000	0
2	2006	19		Actual	Č		6.01127	0.26	106	150,000	15,900,000	0
3	2006	20		Actual	(444	6.09582	0.26	115	150,000	17,250,000	453
4	2006	21		Actual	(6.04737	0.26	110	150,000	16,500,000	0
1	2007	22		Actual	(6.55536	0.26	183	150,000	27,450,000	0
2	2007 2007	23 24		Actual Actual	(6.10032 6.16961	0.26 0.26	116 124	150,000 150,000	17,400,000 18,600,000	0 533
4	2007	25		Actual	(6.12687	0.26	119	150,000	17,850,000	0
1	2008	26		Actual	Ċ		5.80212	0.26	86	150,000	12,900,000	0
2	2008	27		Actual	(5.76519	0.26	83	150,000	12,450,000	0
3	2008	28		Actual	1		5.93754	0.26	98	150,000	14,700,000	386
4 1	2008 2009	29 30		Actual Actual	3		5.71373 6.08450	0.26 0.26	78 113	150,000 150,000	11,700,000 16,950,000	0 0
2	2009	31		Actual	2		5.86079	0.26	90	150,000	13,500,000	0
3	2009	32		Projected				0.26	87	150,000	13,050,000	368
4	2009	33	319	Projected				0.26	83	150,000	12,450,000	0
1	2010	34		Projected				0.26	79	150,000	11,850,000	0
2	2010 2010	35 36		Projected Projected				0.26 0.26	76 73	150,000	11,400,000	0 311
4	2010	36		Projected				0.26	69	150,000 150,000	10,950,000 10,350,000	0
1	2011	38		Projected				0.26	66	150,000	9,900,000	0
2	2011	39		Projected				0.26	63	150,000	9,450,000	0
3	2011	40		Projected				0.26	61	150,000	9,150,000	259
4 1	2011 2012	41 42		Projected				0.26	58 55	150,000	8,700,000	0 0
2	2012	42		Projected Projected				0.26 0.26	53	150,000 150,000	8,250,000 7,950,000	0
3	2012	44		Projected				0.26	50	150,000	7,500,000	216
4	2012	45		Projected				0.26	48	150,000	7,200,000	0
1	2013	46		Projected				0.26	46	150,000	6,900,000	0
2	2013	47		Projected				0.26	44 42	150,000	6,600,000	190
3 4	2013 2013	48 49		Projected Projected				0.26 0.26	42	150,000 150,000	6,300,000 6,000,000	180 0
1	2014	50		Projected				0.26	38	150,000	5,700,000	0
2	2014	51		Projected				0.26	37	150,000	5,550,000	0
3	2014	52		Projected				0.26	35	150,000	5,250,000	150
4	2014	53		Projected				0.26	34	150,000	5,100,000	0
1 2	2015 2015	54 55		Projected Projected				0.26 0.26	32 31	150,000 150,000	4,800,000 4,650,000	0 0
3	2015	56		Projected				0.26	29	150,000	4,350,000	126
4	2015	57		Projected				0.26	28	150,000	4,200,000	0
1	2016	58	104	Projected				0.26	27	150,000	4,050,000	0
2	2016	59		Projected				0.26	26	150,000	3,900,000	0
3	2016	60		Projected Projected				0.26	25	150,000	3,750,000	106
4 1	2016 2017	61 62		Projected				0.26 0.26	23 22	150,000 150,000	3,450,000 3,300,000	0 0
2	2017	63		Projected				0.26	22	150,000	3,300,000	0
3	2017	64		Projected				0.26	21	150,000	3,150,000	88
4	2017	65	76	Projected				0.26	20	150,000	3,000,000	0
1	2018	66		Projected				0.26	19	150,000	2,850,000	0
2	2018	67 69		Projected Projected				0.26	18	150,000	2,700,000	0 74
3 4	2018 2018	68 69		Projected				0.26 0.26	17 16	150,000 150,000	2,550,000 2,400,000	74 0
1	2019	70		Projected				0.26	16	150,000	2,400,000	0
2	2019	71		Projected				0.26	15	150,000	2,250,000	0
3	2019	72	55	Projected				0.26	14	150,000	2,100,000	61

PROJECTED APPROVED CASES BY QUARTER FILED FOR CANCER NON SEC CASES

Exhibit 4

Parameters for fitted curve m -0.0506 7.2373 b Starting 3Q 2004 m -0.0337 6.8631 b Parameters Selected for m -0.0450 7.2500 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = $(3) + (5)$	(7)	-8.00	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
						- (3) + (3)			-(4) X (0)		-(3) X (10)	Approved
								Selected			Estimated	Cases By
Quarter			Number of		Judgmental			Approval	Approved	Case	Ultimate	Fiscal
Filed	Year	t	Cases		Adjustment	у	In(y)	Rate	Cases	Amount	Compensation	Year
4	2019	73		Projected				0.26	14	150,000	2,100,000	0
1	2020	74		Projected				0.26	13	150,000	1,950,000	0
2	2020	75		Projected				0.26	12	150,000	1,800,000	0
3	2020	76		Projected				0.26	12	150,000	1,800,000	51
4	2020	77		Projected				0.26	11	150,000	1,650,000	0
1	2021	78		Projected				0.26	11	150,000	1,650,000	0
2	2021	79		Projected				0.26	10	150,000	1,500,000	0
3	2021	80		Projected				0.26	10	150,000	1,500,000	42
4	2021	81		Projected				0.26	10	150,000	1,500,000	0
1	2022	82		Projected				0.26	9	150,000	1,350,000	0
2	2022	83		Projected				0.26	9	150,000	1,350,000	0
3	2022	84		Projected				0.26	8	150,000	1,200,000	36
4	2022	85		Projected				0.26	8	150,000	1,200,000	0
1	2023	86		Projected				0.26	8	150,000	1,200,000	0
2	2023	87		Projected				0.26	7	150,000	1,050,000	0
3	2023	88		Projected				0.26	7	150,000	1,050,000	30
4	2023	89		Projected				0.26	7	150,000	1,050,000	0
1	2024	90		Projected				0.26	7	150,000	1,050,000	0
2	2024	91		Projected				0.26	6	150,000	900,000	0
3	2024	92		Projected				0.26	6	150,000	900,000	26
4	2024	93		Projected				0.26	5	150,000	750,000	0
1	2025	94		Projected				0.26	5	150,000	750,000	0
2	2025	95		Projected				0.26	5	150,000	750,000	0
3	2025	96		Projected				0.26	5	150,000	750,000	20
4	2025	97		Projected				0.26	5	150,000	750,000	0
1	2026	98		Projected				0.26	4	150,000	600,000	0
2	2026	99		Projected				0.26	4	150,000	600,000	0
3	2026	100		Projected				0.26	4	150,000	600,000	17
4	2026	101		Projected				0.26	4	150,000	600,000	0
1	2027	102		Projected				0.26	4	150,000	600,000	0
2	2027	103		Projected				0.26	4	150,000	600,000	0
3	2027	104		Projected				0.26	3	150,000	450,000	15
4	2027	105		Projected				0.26	3	150,000	450,000	0
1	2028	106		Projected				0.26	3	150,000	450,000	0
2	2028	107		Projected				0.26	3	150,000	450,000	0
3	2028	108		Projected				0.26	3	150,000	450,000	12
4	2028	109		Projected				0.26	3	150,000	450,000	0
1	2029	110		Projected				0.26	3	150,000	450,000	0
2	2029	111		Projected				0.26	3	150,000	450,000	0
3	2029	112		Projected				0.26	2	150,000	300,000	11
4	2029	113		Projected				0.26	2	150,000	300,000	0
1	2030	114		Projected				0.26	2	150,000	300,000	0
2	2030	115		Projected				0.26	2	150,000	300,000	0
3	2030	116	8	Projected				0.26	2	150,000	300,000	8
			33,581						8,725		1,308,750,000	8,725

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

36 10/7/2009

PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM SENSITIVITY CASES

Exhibit 4

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter Filed	Year	t	Number of Cases		Judgmental Adjustment	V	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
3	2001	·	188 Ac	etual	Aujustinent (y) 188	5.23644	0.57	107	0	0	107
4	2001	1	112 Ac		Č		4.71850	0.57	64	0	0	0
1	2002	2	143 Ac		(4.96284	0.57	82	0	0	0
2	2002	3	185 Ac		(5.22036	0.57	105	0	0	0
3	2002	4	152 Ac		(5.02388	0.57	87	0	0	338
4	2002	5	90 Ac	ctual	(90	4.49981	0.57	51	0	0	0
1	2003	6	83 Ac		(4.41884	0.57	47	0	0	0
2	2003	7	90 Ac		(4.49981	0.57	51	0	0	0
3	2003	8	71 Ac		(4.26268	0.57	40	0	0	189
4	2003	9	51 Ac		(3.93183	0.57	29	0	0	0
1 2	2004 2004	10 11	48 Ac 44 Ac		(3.87120 3.78419	0.57 0.57	27 25	0	0	0
3	2004	12	115 Ac		(4.74493	0.57	66	0	0	147
4	2004	13	30 Ac		(3.40120	0.57	17	0	0	0
1	2005	14	56 Ac		(4.02535	0.57	32	0	0	0
2	2005	15	53 Ac		(3.97029	0.57	30	0	0	0
3	2005	16	44 Ac	ctual	() 44	3.78419	0.57	25	0	0	104
4	2005	17	27 Ac	ctual	(3.29584	0.57	15	0	0	0
1	2006	18	25 Ac		(3.21888	0.57	14	0	0	0
2	2006	19	45 Ac		(3.80666	0.57	26	0	0	0
3	2006	20	44 Ac		(3.78419	0.57	25	0	0	80
4	2006	21	69 Ac		(4.23411	0.57	39	0	0	0
1 2	2007 2007	22 23	67 Ac 42 Ac		(4.20469 3.73767	0.57	38 24	0	0	0
3	2007	23 24	63 Ac		(4.14313	0.57 0.57	36	0	0	137
4	2007	25	39 Ac		(3.66356	0.57	22	0	0	0
1	2008	26	41 Ac		Č		3.71357	0.57	23	0	0	0
2	2008	27	40 Ac		(3.68888	0.57	23	0	0	0
3	2008	28	35 Ac			1 36	3.58352	0.57	20	0	0	88
4	2008	29	24 Ac	ctual	2		3.25810	0.57	14	0	0	0
1	2009	30	38 Ac		:		3.71357	0.57	22	0	0	0
2	2009	31	35 Ac		4	4 39	3.66356	0.57	20	0	0	0
3	2009	32		ojected				0.57	17	0	0	73
4	2009	33		ojected				0.57	16	0	0	0
1 2	2010 2010	34 35		ojected ojected				0.57 0.57	15 15	0	0	0
3	2010	36		ojected				0.57	14	0	0	60
4	2010	37		ojected				0.57	14	0	0	0
1	2011	38		ojected				0.57	13	0	0	0
2	2011	39		ojected				0.57	13	0	0	0
3	2011	40	21 Pr	ojected				0.57	12	0	0	52
4	2011	41		ojected				0.57	11	0	0	0
1	2012	42		ojected				0.57	11	0	0	0
2	2012	43		ojected				0.57	10	0	0	0
3 4	2012	44 45		ojected				0.57	10 10	0	0	42
1	2012 2013	46		ojected ojected				0.57 0.57	9	0	0	0
2	2013	47		ojected				0.57	9	0	0	0
3	2013	48		ojected				0.57	9	0	0	37
4	2013	49		ojected				0.57	8	0	0	0
1	2014	50	14 Pr	ojected				0.57	8	0	0	0
2	2014	51	13 Pr	ojected				0.57	7	0	0	0
3	2014	52		ojected				0.57	7	0	0	30
4	2014	53		ojected				0.57	7	0	0	0
1	2015	54		ojected				0.57	7	0	0	0
2	2015	55 56		ojected				0.57	6	0	0	0 26
4	2015 2015	56 57		ojected ojected				0.57 0.57	6 6	0	0	0
1	2016	58		ojected				0.57	6	0	0	0
2	2016	59		ojected				0.57	5	0	0	0
3	2016	60		ojected				0.57	5	0	0	22
4	2016	61		ojected				0.57	5	0	0	0
1	2017	62		ojected				0.57	5	0	0	0
2	2017	63		ojected				0.57	5	0	0	0
3	2017	64		ojected				0.57	5	0	0	20
4	2017	65		ojected				0.57	4	0	0	0
1 2	2018 2018	66 67		ojected ojected				0.57 0.57	4 4	0	0	0
3	2018	68		ojected				0.57	4	0	0	16
4	2018	69		ojected				0.57	3	0	0	0
1	2019	70		ojected				0.57	3	0	0	0
									_	-	•	-

PROJECTED APPROVED CASES BY QUARTER FILED FOR BERYLLIUM SENSITIVITY CASES

Exhibit 4

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter			Number of		Judgmental			Selected Approval	Approved	Case	Estimated Ultimate	Approved Cases By Fiscal
Filed	Year	t	Cases		Adjustment	у	ln(y)	Rate	Cases	Amount	Compensation	Year
2	2019	71		Projected	Adjustinont	y	" (y)	0.57	3	0	0	0
3	2019	72		Projected				0.57	3	0	0	12
4	2019	73		Projected				0.57	3	0	0	0
1	2020	74		Projected				0.57	3	0	0	Ö
2	2020	75		Projected				0.57	3	0	0	Ö
3	2020	76		Projected				0.57	3	0	0	12
4	2020	77		Projected				0.57	2	0	0	0
1	2021	78		Projected				0.57	2	0	0	ő
2	2021	79		Projected				0.57	2	0	0	Ō
3	2021	80		Projected				0.57	2	0	0	8
4	2021	81		Projected				0.57	2	0	0	Ō
1	2022	82		Projected				0.57	2	0	0	0
2	2022	83		Projected				0.57	2	0	0	Ō
3	2022	84		Projected				0.57	2	0	0	8
4	2022	85		Projected				0.57	2	0	0	Ō
1	2023	86		Projected				0.57	2	0	0	0
2	2023	87		Projected				0.57	2	0	0	Ö
3	2023	88		Projected				0.57	2	0	0	8
4	2023	89		Projected				0.57	2	0	0	0
1	2024	90		Projected				0.57	2	0	0	0
2	2024	91		Projected				0.57	2	0	0	0
3	2024	92		Projected				0.57	1	0	0	7
4	2024	93		Projected				0.57	1	0	0	0
1	2025	94		Projected				0.57	1	0	0	0
2	2025	95		Projected				0.57	1	0	0	0
3	2025	96		Projected				0.57	1	0	0	4
4	2025	97	2	Projected				0.57	1	0	0	0
1	2026	98	2	Projected				0.57	1	0	0	0
2	2026	99	2	Projected				0.57	1	0	0	0
3	2026	100	2	Projected				0.57	1	0	0	4
4	2026	101	2	Projected				0.57	1	0	0	0
1	2027	102	2	Projected				0.57	1	0	0	0
2	2027	103	2	Projected				0.57	1	0	0	0
3	2027	104	1	Projected				0.57	1	0	0	4
4	2027	105	1	Projected				0.57	1	0	0	0
1	2028	106	1	Projected				0.57	1	0	0	0
2	2028	107	1	Projected				0.57	1	0	0	0
3	2028	108	1	Projected				0.57	1	0	0	4
4	2028	109	1	Projected				0.57	1	0	0	0
1	2029	110	1	Projected				0.57	1	0	0	0
2	2029	111	1	Projected				0.57	1	0	0	0
3	2029	112		Projected				0.57	1	0	0	4
4	2029	113		Projected				0.57	1	0	0	0
1	2030	114		Projected				0.57	1	0	0	0
2	2030	115		Projected				0.57	1	0	0	0
3	2030	116	1	Projected				0.57	1	0	0	4
			0.005						1,647		0	1 647
			2,885						1,647		0	1,647

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

PROJECTED APPROVED CASES BY QUARTER FILED FOR PART E CASES

Exhibit 4

Parameters for fitted curve m -0.0191 7.7554 b -0.0344 8.1268 Starting 3Q 2004 Parameters Selected for m -0.0300 8.0000 b

CASES BY QUARTER

CASES BY	QUARTER										
	(1)	(2)	(3) (4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12) Approved
							Selected			Estimated	Cases By
Quarter			Number of	Judgmental			Approval	Approved	Case	Ultimate	Fiscal
Filed 3	Year 2001	t	Cases 2,181 Actual	Adjustment	y 0 2181	In(y) 7.68754	Rate 0.44	Cases 960	Amount 143,000	Compensation 137,280,000	Year 960
4	2001	1	2,058 Actual		0 2058	7.62949	0.44	906	143,000	129,558,000	0
1 2	2002 2002	2	2,823 Actual 2,413 Actual		0 2823 0 2413	7.94556 7.78863	0.44 0.44	1242 1062	143,000 143,000	177,606,000 151,866,000	0
3	2002	4	2,058 Actual		0 2058	7.62949	0.44	906	143,000	129,558,000	4116
4	2002	5	1,714 Actual		0 1714	7.44659	0.44	754	143,000	107,822,000	0
1 2	2003 2003	6 7	1,604 Actual 2,160 Actual		0 1604 0 2160	7.38026 7.67786	0.44 0.44	706 950	143,000 143,000	100,958,000 135,850,000	0
3	2003	8	2,045 Actual		0 2045	7.62315	0.44	900	143,000	128,700,000	3310
4	2003	9	1,826 Actual		0 1826	7.50988	0.44	803	143,000	114,829,000	0
1	2004 2004	10 11	1,843 Actual		0 1843	7.51915 7.04054	0.44	811	143,000	115,973,000	0
2	2004	12	1,142 Actual 1,336 Actual		0 1142 0 1336	7.19744	0.44 0.44	502 588	143,000 143,000	71,786,000 84,084,000	2704
4	2004	13	1,747 Actual		0 1747	7.46566	0.44	769	143,000	109,967,000	0
1 2	2005 2005	14 15	2,910 Actual		0 2910 0 3685	7.97591 8.21203	0.44 0.44	1280 1621	143,000	183,040,000 231,803,000	0
3	2005	16	3,685 Actual 2,278 Actual		0 2278	7.73105	0.44	1002	143,000 143,000	143,286,000	4672
4	2005	17	1,795 Actual		0 1795	7.49276	0.44	790	143,000	112,970,000	0
1 2	2006 2006	18 19	1,710 Actual 1,480 Actual		0 1710 0 1480	7.44425 7.29980	0.44 0.44	752 651	143,000 143,000	107,536,000 93,093,000	0
3	2006	20	1,588 Actual		0 1588	7.25560	0.44	699	143,000	99,957,000	2892
4	2006	21	1,639 Actual		0 1639	7.40184	0.44	721	143,000	103,103,000	0
1	2007	22 23	2,060 Actual		0 2060	7.63046	0.44	906	143,000	129,558,000	0
2	2007 2007	23	1,426 Actual 1,429 Actual		0 1426 0 1429	7.26263 7.26473	0.44 0.44	627 629	143,000 143,000	89,661,000 89,947,000	0 2883
4	2007	25	1,339 Actual		0 1339	7.19968	0.44	589	143,000	84,227,000	0
1	2008	26	1,206 Actual		0 1206	7.09506	0.44	531	143,000	75,933,000	0
2	2008 2008	27 28	1,363 Actual 1,372 Actual		0 1363 0 1372	7.21744 7.22402	0.44 0.44	600 604	143,000 143,000	85,800,000 86,372,000	0 2324
4	2008	29	1,153 Actual		0 1153	7.05012	0.44	507	143,000	72,501,000	0
1	2009	30	1,368 Actual		0 1368	7.22111	0.44	602	143,000	86,086,000	0
2	2009 2009	31 32	1,106 Actual 1,141 Projected		0 1106	7.00851	0.44 0.44	487 502	143,000 143,000	69,641,000 71,786,000	0 2098
4	2009	33	1,108 Projected				0.44	488	143,000	69,784,000	0
1	2010	34	1,075 Projected				0.44	473	143,000	67,639,000	0
2	2010 2010	35 36	1,043 Projected				0.44 0.44	459 445	143,000 143,000	65,637,000 63,635,000	0 1865
4	2010	37	1,012 Projected 982 Projected				0.44	432	143,000	61,776,000	0
1	2011	38	953 Projected				0.44	419	143,000	59,917,000	0
2	2011 2011	39 40	925 Projected				0.44 0.44	407 395	143,000 143,000	58,201,000 56,485,000	0 1653
4	2011	41	898 Projected 871 Projected				0.44	383	143,000	54,769,000	0
1	2012	42	846 Projected				0.44	372	143,000	53,196,000	0
2	2012	43 44	821 Projected				0.44 0.44	361 350	143,000	51,623,000	0 1466
4	2012	44	796 Projected 773 Projected				0.44	340	143,000 143,000	50,050,000 48,620,000	0
1	2013	46	750 Projected				0.44	330	143,000	47,190,000	0
2	2013	47	728 Projected				0.44	320	143,000	45,760,000	0
3 4	2013 2013	48 49	706 Projected 685 Projected				0.44 0.44	311 301	143,000 143,000	44,473,000 43.043.000	1301 0
1	2014	50	665 Projected				0.44	293	143,000	41,899,000	0
2	2014	51	645 Projected				0.44	284	143,000	40,612,000	0
3 4	2014 2014	52 53	626 Projected 608 Projected				0.44 0.44	275 268	143,000 143,000	39,325,000 38,324,000	1153 0
1	2015	54	590 Projected				0.44	260	143,000	37,180,000	0
2	2015	55	572 Projected				0.44	252	143,000	36,036,000	0
3 4	2015 2015	56 57	556 Projected 539 Projected				0.44 0.44	245 237	143,000 143,000	35,035,000 33,891,000	1025 0
1	2016	58	523 Projected				0.44	230	143,000	32,890,000	0
2	2016	59	508 Projected				0.44	224	143,000	32,032,000	0
3 4	2016 2016	60 61	493 Projected				0.44 0.44	217 210	143,000 143,000	31,031,000 30,030,000	908 0
1	2017	62	478 Projected 464 Projected				0.44	204	143,000	29,172,000	0
2	2017	63	450 Projected				0.44	198	143,000	28,314,000	0
3 4	2017 2017	64 65	437 Projected 424 Projected				0.44 0.44	192 187	143,000	27,456,000	804 0
1	2017	66	412 Projected				0.44	181	143,000 143,000	26,741,000 25,883,000	0
2	2018	67	399 Projected				0.44	176	143,000	25,168,000	0
3	2018 2018	68 69	388 Projected				0.44	171	143,000	24,453,000	715
4 1	2018	70	376 Projected 365 Projected				0.44 0.44	165 161	143,000 143,000	23,595,000 23,023,000	0
2	2019	71	354 Projected				0.44	156	143,000	22,308,000	0
3 4	2019	72 73	344 Projected				0.44	151	143,000	21,593,000	633
4 1	2019 2020	73 74	334 Projected 324 Projected				0.44 0.44	147 143	143,000 143,000	21,021,000 20,449,000	0
2	2020	75	314 Projected				0.44	138	143,000	19,734,000	0
3	2020	76	305 Projected				0.44	134	143,000 143,000	19,162,000 18,590,000	562
4	2020 2021	77 78	296 Projected 287 Projected				0.44 0.44	130 126	143,000	18,018,000	0
2	2021	79	279 Projected				0.44	123	143,000	17,589,000	0
3	2021	80	270 Projected				0.44	119	143,000	17,017,000	498
4	2021 2022	81 82	262 Projected 255 Projected				0.44 0.44	115 112	143,000 143,000	16,445,000 16,016,000	0
2	2022	83	247 Projected				0.44	109	143,000	15,587,000	0
3	2022	84	240 Projected				0.44	106	143,000	15,158,000	442
4	2022 2023	85 86	233 Projected 226 Projected				0.44 0.44	103 99	143,000 143,000	14,729,000 14,157,000	0
2	2023	87	219 Projected				0.44	96	143,000	13,728,000	0
3	2023	88	213 Projected				0.44	94	143,000	13,442,000	392
4	2023 2024	89 90	206 Projected				0.44 0.44	91 88	143,000 143,000	13,013,000	0
2	2024	90	200 Projected 194 Projected				0.44	88 85	143,000	12,584,000 12,155,000	0
3	2024	92	189 Projected				0.44	83	143,000	11,869,000	347
4	2024 2025	93 94	183 Projected				0.44 0.44	81 78	143,000 143,000	11,583,000	0
2	2025	94 95	178 Projected 172 Projected				0.44	78 76	143,000	11,154,000 10,868,000	0
3	2025	96	167 Projected				0.44	73	143,000	10,439,000	308
4	2025	97 98	162 Projected 158 Projected				0.44	71	143,000	10,153,000	0
1 2	2026 2026	98 99	158 Projected 153 Projected				0.44 0.44	70 67	143,000 143,000	10,010,000 9,581,000	0
3	2026	100	148 Projected				0.44	65	143,000	9,295,000	273
4 1	2026 2027	101 102	144 Projected 140 Projected				0.44 0.44	63 62	143,000 143,000	9,009,000 8,866,000	0
	2021	102	1-to Frojected				0.44	02	170,000	0,000,000	U

39 10/7/2009

PROJECTED APPROVED CASES BY QUARTER FILED FOR PART E CASES

Exhibit 4

Parameters for fitted curve m -0.0191 7.7554 b -0.0344 8.1268 Starting 3Q 2004 Parameters Selected for m -0.0300 8.0000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
								Selected			Estimated	Approved Cases By
Quarter			Number of		Judgmental			Approval	Approved	Case	Ultimate	Fiscal
Filed 2	Year 2027	t 103	Cases	Droinatad	Adjustment	У	ln(y)	Rate	Cases 60	Amount	Compensation	Year 0
3	2027	103		Projected Projected				0.44 0.44	58	143,000 143,000	8,580,000 8,294,000	243
4	2027	105	128	Projected				0.44	56	143,000	8,008,000	0
1	2028	106		Projected				0.44	55	143,000	7,865,000	0
2	2028 2028	107 108		Projected Projected				0.44 0.44	53 51	143,000 143,000	7,579,000 7,293,000	0 215
4	2028	109		Projected				0.44	50	143,000	7,150,000	0
1	2029	110	110	Projected				0.44	48	143,000	6,864,000	0
2	2029	111		Projected				0.44	47	143,000	6,721,000	0
3 4	2029 2029	112 113	104	Projected Projected				0.44 0.44	46 44	143,000 143,000	6,578,000 6,292,000	191 0
1	2030	114	98	Projected				0.44	43	143,000	6.149.000	0
2	2030	115	95	Projected				0.44	42	143,000	6,006,000	0
3	2030	116	92	Projected				0.44	40	143,000	5,720,000	169
4 1	2030 2031	116 117	92	Projected Projected				0.44 0.44	40 39	143,000 143,000	5,720,000 5,577,000	0
2	2031	118		Projected				0.44	38	143,000	5,434,000	0
3	2031	119	84	Projected				0.44	37	143,000	5,291,000	154
4	2031	120	81	Projected				0.44	36	143,000	5,148,000	0
1 2	2032 2032	121 122		Projected Projected				0.44 0.44	35 34	143,000 143,000	5,005,000 4,862,000	0
3	2032	123	74	Projected				0.44	33	143,000	4,719,000	138
4	2032	124	72	Projected				0.44	32	143,000	4,576,000	0
1	2033	125	70	Projected				0.44	31	143,000	4,433,000	0
2	2033	126 127		Projected Projected				0.44	30 29	143,000 143,000	4,290,000 4,147,000	0 122
4	2033	128	64	Projected				0.44	28	143,000	4,004,000	0
1	2034	129	62	Projected				0.44	27	143,000	3,861,000	0
2	2034 2034	130	60	Projected				0.44	26 26	143,000	3,718,000	0 107
3 4	2034	131 132	59 57	Projected Projected				0.44 0.44	26 25	143,000 143,000	3,718,000 3,575,000	107
1	2035	133		Projected				0.44	24	143,000	3,432,000	0
2	2035	134		Projected				0.44	24	143,000	3,432,000	0
3	2035 2035	135		Projected				0.44	23	143,000	3,289,000	96
4	2035	136 137		Projected Projected				0.44 0.44	22	143,000 143,000	3,146,000 3,146,000	0
2	2036	138		Projected				0.44	21	143,000	3,003,000	0
3	2036	139	46	Projected				0.44	20	143,000	2,860,000	85
4	2036	140		Projected				0.44 0.44	20	143,000	2,860,000	0
1 2	2037 2037	141 142	43	Projected Projected				0.44	19 18	143,000 143,000	2,717,000 2,574,000	0
3	2037	143		Projected				0.44	18	143,000	2,574,000	75
4	2037	144	40	Projected				0.44	18	143,000	2,574,000	0
1	2038 2038	145 146	38	Projected				0.44	17	143,000	2,431,000	0
2	2038	146		Projected Projected				0.44	16 16	143,000 143,000	2,288,000 2,288,000	67
4	2038	148	35	Projected				0.44	15	143,000	2,145,000	0
1	2039	149		Projected				0.44	15	143,000	2,145,000	0
2	2039 2039	150 151		Projected				0.44 0.44	15 14	143,000	2,145,000	0 59
3 4	2039	152		Projected Projected				0.44	14	143,000 143,000	2,002,000 2,002,000	0
1	2040	153	30	Projected				0.44	13	143,000	1,859,000	0
2	2040	154		Projected				0.44	13	143,000	1,859,000	0
3 4	2040 2040	155 156		Projected Projected				0.44 0.44	13 12	143,000 143,000	1,859,000 1,716,000	53 0
1	2041	157		Projected				0.44	12	143,000	1,716,000	0
2	2041	158	26	Projected				0.44	11	143,000	1,573,000	0
3	2041	159		Projected				0.44	11	143,000	1,573,000	46
4	2041 2042	160 161		Projected Projected				0.44 0.44	11 11	143,000 143,000	1,573,000 1,573,000	0
2	2042	162	23	Projected				0.44	10	143,000	1,430,000	0
3	2042	163	22	Projected				0.44	10	143,000	1,430,000	42
4	2042	164		Projected				0.44	10	143,000	1,430,000	0
1 2	2043 2043	165 166		Projected Projected				0.44 0.44	9	143,000 143,000	1,287,000 1,287,000	0
3	2043	167	20	Projected				0.44	9	143,000	1,287,000	37
4	2043	168	19	Projected				0.44	8	143,000	1,144,000	0
1	2044	169		Projected				0.44	8	143,000	1,144,000	0
2	2044 2044	170 171		Projected Projected				0.44 0.44	8	143,000 143,000	1,144,000 1,144,000	0 32
4	2044	172		Projected				0.44	7	143,000	1,001,000	0
1	2045	173	17	Projected				0.44	7	143,000	1,001,000	0
2	2045	174		Projected				0.44	7	143,000	1,001,000	0
3	2045	175	16	Projected				0.44	7	143,000	1,001,000	28
			96,051						42,263		6,043,609,000	42,263

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve Column (8) is from Exhibit 1 Page 2 Table 2 Column (12) is the sum of column (9) for rows in the fiscal year

Table 1								
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Filing Date	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART E	TOTAL
7/01-9/01	1,459	437	22	1,820	924	107	960	5,729
10/01-9/02	1,030	576	29	2,845	1,950	338	4,116	10,884
10/02-9/03	488	302	8	1,469	836	189	3,310	6,602
10/03-9/04	583	383	10	1,497	796	147	2,704	6,120
10/04-9/05	815	208	10	1,202	640	104	4,672	7,651
10/05-9/06	766	81	5	1,069	453	80	2,892	5,346
10/06-9/07	713	100	8	1,181	533	137	2,883	5,555
10/07-9/08	525	62	7	1,411	386	88	2,324	4,803
10/08-9/09	342	43	4	1,244	368	73	2,098	4,172
10/09-9/10	312	31	4	1,042	311	60	1,865	3,625
10/10-9/11	269	22	4	953	259	52	1,653	3,212
10/11-9/12	231	15	4	870	216	42	1,466	2,844
10/12-9/13	197	11	4	796	180	37	1,301	2,526
10/13-9/14	173	8	4	727	150	30	1,153	2,245
10/14-9/15	147	6	1	665	126	26	1,025	1,996
10/15-9/16	126	4	0	607	106	22	908	1,773
10/16-9/17	110	4	0	554	88	20	804	1,580
10/17-9/18	94	4	0	508	74	16	715	1,411
10/18-9/19	81	4	0	464	61	12	633	1,255
10/19-9/20	69	0	0	423	51	12	562	1,117
10/20-9/21	59	0	0	387	42	8	498	994
10/21-9/22	50	0	0	354	36	8	442	890
10/22-9/23	42	0	0	324	30	8	392	796
10/23-9/24	39	0	0	296	26	7	347	715
10/24-9/25	34	0	0	271	20	4	308	637
10/25-9/26	30	0 0	0	246	17 15	4	273 243	570
10/26-9/27 10/27-9/28	26 22	0	0	226 206	12	4	243 215	514 459
10/28-9/29	19	0	0	188	12	4	191	413
10/29-9/30	16	0	0	173	8	4	169	370
10/30-9/31	10	U	U	173	0	7	154	154
10/31-9/32							138	138
10/32-9/33							122	122
10/33-9/34							107	107
10/34-9/35							96	96
10/35-9/36							85	85
10/36-9/37							75	75
10/37-9/38							67	67
10/38-9/39							59	59
10/39-9/40							53	53
10/40-9/41							46	46
10/41-9/42							42	42
10/42-9/43							37	37
10/43-9/44							32	32
10/44-9/45							28	28
Total	8,867	2,301	124	24,018	8,725	1,647	42,263	87,945

Columns (2) - (8) Data are from Exhibit 4 Column (12) for the respective disease

Table 2

			ESTIMAT	TED NUMBER	OF PAID CASE	S BY FISCA	L YEAR	
								BS Claims
Fiscal Yr Pd	RECA	BD	CS	CN - SEC	CN-NON SEC	PART E	TOTAL	Approved
7/01-9/01	56	1	0	35	0	0	92	0
10/01-9/02	1,778	405	25	1,299	3	0	3,510	137
10/02-9/03	766	392	16	1,240	135	0	2,549	395
10/03-9/04	572	295	5	673	493	0	2,038	108
10/04-9/05	578	234	11	788	968	1,555	4,134	70
10/05-9/06	472	198	6	1,365	1,343	2,176	5,560	62
10/06-9/07	1,023	156	12	1,474	1,137	3,218	7,020	172
10/07-9/08	722	145	7	2,201	706	4,453	8,234	159
10/08-9/09	451	116	9	2,219	487	4,228	7,510	119
10/09-9/10	335	85	8	1,484	600	3,186	5,698	81
10/10-9/11	304	73	8	1,282	451	2,627	4,745	72
10/11-9/12	261	63	4	1,193	433	2,401	4,355	42
10/12-9/13	223	56	4	1,110	376	2,168	3,937	37
10/13-9/14	189	52	4	1,036	324	1,955	3,560	30
10/14-9/15	173	8	4	727	216	1,768	2,896	26
10/15-9/16	147	6	1	665	180	1,603	2,602	22
10/16-9/17	126	4	0	607	150	1,455	2,342	20
10/17-9/18	110	4	0	554	126	1,327	2,121	16
10/18-9/19	94	4	0	508	106	1,210	1,922	12
10/19-9/20	81	4	0	464	88	804	1,441	12
10/20-9/21	69	0	0	423	74	715	1,281	8
10/21-9/22	59	0	0	387	61	633	1,140	8
10/22-9/23	50	0	0	354	51	562	1,017	8
10/23-9/24	42	0	0	324	42	498	906	7
10/24-9/25	39	0	0	296	36	442	813	4
10/25-9/26	34	0	0	271	30	392	727	4
10/26-9/27	30	0	0	246	26	347	649	4
10/27-9/28	26	0	0	226	20	308	580	4
10/28-9/29	22	0	0	206	17	273	518	4
10/29-9/30	19	0	0	188	15	243	465	4
10/30-9/31	16	0	0	173	12	215	416	0
10/31-9/32		0	0	0	11	191	202	0
10/32-9/33					8	169	177	
10/33-9/34					0	154	154	
10/34-9/35						138	138	
10/35-9/36						122	122	
10/36-9/37						107	107	
10/37-9/38						96	96	
10/38-9/39						85	85	
10/39-9/40						75	75	
10/40-9/41						67	67	
10/41-9/42						59	59	
10/42-9/43						53	53	
10/43-9/44						46	46	
10/44-9/45						42	42	
10/45-9/46						37	37	
10/46-9/47						32	32	
10/47-9/48						28	28	
10/48-9/49						0	0	
10/49-9/50								
Total	8,867	2,301	124	24,018	8,725	42,263	86,298	1,647
	,	,		,	, -	,	, -	,-

The first eight rows for each disease are actual data from Exhibit 3 Page 3 Table 9. For 10/08-9/09 the number of claims paid in the last quarter is assumed to be the same as the number paid in the prior quarter. For RECA, the 10/09-9/10 fiscal year is calculated as the number of cases approved from 10/08-9/09 from Table 1 plus a correction term of 1/5 of the difference in the number of cases approved from 7/01 through 9/08 from Table 1 and the number of cases approved from 7/01 through 9/09 from the first eight rows of this table. This is based on an assumption that RECA cases are paid one year after they are filed. The remaining fiscal years are calculated as the number of claims approved in the prior year with fiscal years through 10/13-9/14 containing the correction term.

The remaining Part B diseases are similar with the assumption used is that a case is paid one year after it is filed for BD, CS, CN-SEC and three years for CN-NONSEC. The correction term is spread over 5 years for RECA, BD, CN-SEC and CN-NONSEC. There is no correction term for CS. Part E claims are assumed to be paid 3 years after they are filed (1 year from filling to approval and 2 years duration of payments). The correction term for Part E is spread over 10 years.

The number of BD cases includes BS cases paid and the number of RECA cases includes cases from all other otherwise non-covered diseases.

Table 3

ESTIMATED CASES ELIGIBLE FOR MEDICAL EXPENSES

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8) PART B	(9) PART E	(10) PART B	(11) PART E
Filing Date	RECA	BD	CS CI	N - SEC	CN-NON SEC	BS	NEW MEDICAL	NEW MEDICAL	ONGOING MEDICAL	ONGOING MEDICAL
7/01-9/01 10/01-9/02 10/02-9/03 10/03-9/04 10/04-9/05 10/05-9/06 10/06-9/07 10/07-9/08 10/08-9/09 10/09-9/10 10/10-9/11 10/11-9/12 10/12-9/13 10/13-9/14 10/14-9/15 10/15-9/16 10/16-9/17 10/17-9/18 10/18-9/19 10/19-9/20 10/20-9/21 10/21-9/22 10/22-9/23 10/23-9/24 10/24-9/25 10/25-9/26 10/26-9/27 10/27-9/28 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/28-9/29 10/38-9/39 10/38-9/39 10/38-9/40 10/41-9/42 10/42-9/43 10/43-9/44 10/44-9/45 10/45-9/46 10/46-9/47 10/47-9/48 10/48-9/59 10/55-9/51 10/55-9/51	RECA 37 589 273 303 380 343 727 423 258 171 155 133 114 97 88 75 64 48 41 35 30 62 21 20 17 15 13 11 10 8	BD 0 321 234 138 97 102 70 85 77 40 35 31 129 4 3 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	CS CI	N - SEC 133 5066 3333 199 227 4255 4022 4628 6784 470 3300 3022 275 2511 192 211 192 1161 147 134 112 103 93 95 0 0	CN-NON SEC 0 0 23 140 300 519 450 276 231 282 212 203 177 152 101 85 70 59 50 41 35 29 24 20 17 14 12 9 8 7 6 5 4	BS 0 137 395 108 70 62 172 159 119 811 72 42 37 30 26 22 20 16 12 8 8 8 7 7 4 4 4 4 4 4 0 0 0 0	MEDICAL 50 1,568 1,266 892 1,081 1,457 1,826 1,576 1,317 1,260 1,066 957 866 781 552 488 431 384 343 307 270 243 219 195 175 158 143 129 116 106 93 5 4 0	MEDICAL 0 0 0 0 0 0 0 2 121 1,281 2,575 3,006 1,808 1,490 1,362 1,230 1,109 1,003 909 825 753 686 456 4406 359 319 283 251 222 197 175 155 138 122 108 96 87 78 69 61 54 48 43 38 33 30 26 24 21 18 16	50 1,615 2,793 3,529 4,408 5,606 7,096 8,242 9,049 9,735 10,167 10,433 10,588 10,086 9,722 9,313 8,868 8,400 7,910 7,414 6,919 6,427 5,945 5,479 5,030 4,601 4,195 5,479 5,030 4,601 4,195 5,479 1,100	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10/55-9/56 10/56-9/57 10/57-9/58 10/58-9/59 10/59-9/60									26 19 14 9 6	200 169 142 119 99
Total	4,581	1,321	77	9,137	3,561	1,647	20,324	22,093	232,610	252,452

The first eight rows of the new medical are from Exhibit 3 Table 10. The third quarter 2009 is estimated to be the same as the prior quarter. For each disease, the number of new cases eligible for medical payments is the estimated number of paid cases from Exhibit 5 Table 1 times the percentage filed by a living employee from Exhibit 1 Page 2 Table 3 times a mortality factor based on the assumption that the percentage of living employees filing claims will decrease over time.

The age at filing a claim is assumed to be 67. The claimants from the prior year are 68 and 2 years prior 69, etc. The probabilities of living an additional year are from Exhibit 1 Table 4.

The ongoing medical is estimated as the new medical plus each prior years new medical with a mortality factor applied.

Part B medical in column (8) is the sum of columns (2) through (7).

Assumes that a claimant is eligible for medical treatment in the same year as the claim is paid.

ESTIMATED DOLLARS PAID BY FISCAL YEAR

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13) = (9) + (12)
Paid Fisc Yr	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART B MEDICAL	PART B TOTAL	PART E COMPENSATION	PART E MEDICAL	PART E TOTAL	COMBINED PARTS B AND E TOTAL
7/01-9/01	2,800,000	150,000	0	5,250,000	0	0	-1,289,764	6,910,236	0	-69,723	-69,723	\$6,840,513
10/01-9/02	89,295,000	60,011,586	3,750,000	194,850,000	450,000	0	3,822,401	352,178,987	0		0	\$352,178,987
10/02-9/03	39,122,020	58,563,006	2,400,000	186,000,000	20,250,000	0	14,739,059	321,074,085	0		0	\$321,074,085
10/03-9/04 10/04-9/05	28,870,000 86,294,840	44,183,172 35,025,000	750,000 1,650,000	100,750,000 118,020,000	73,912,500 145,075,000	0	23,002,548 32,600,271	271,468,219 418,665,110	0 200,208,207	177,569	0 200,385,776	\$271,468,219 \$619,050,887
10/04-9/05	105,430,556	29,700,000	900,000	204,332,877	201,132,947	0	39,314,951	580,811,331	281,750,900	2,318,881	284,069,781	\$864,881,112
10/06-9/07	129,397,071	23,210,163	1,800,000	219,899,643	169,970,000	0	55,392,766	599,669,642	373,520,197	5,103,057	378,623,254	\$978,292,897
10/07-9/08	81,923,730	21,547,500	1,050,000	327,858,214	105,503,571	Ō	82,303,415	620,186,431	472,430,858	10,772,546	483,203,404	\$1,103,389,834
10/08-9/09	60,909,127	18,560,000	1,400,000	350,921,155	72,828,250	0	76,535,867	581,154,398	407,188,956	14,518,280	421,707,236	\$1,002,861,635
10/09-9/10	50,250,000	12,750,000	1,200,000	222,600,000	90,000,000	0	92,871,900	469,671,900	455,598,000	30,844,600	486,442,600	\$956,114,500
10/10-9/11	45,600,000	10,950,000	1,200,000	192,300,000	67,650,000	0	102,808,704	420,508,704	375,661,000	36,803,836	412,464,836	\$832,973,540
10/11-9/12	39,150,000	9,450,000	600,000	178,950,000	64,950,000	0	111,938,517	405,038,517	343,343,000	42,499,310	385,842,310	\$790,880,827
10/12-9/13 10/13-9/14	33,450,000 28,350,000	8,400,000 7,800,000	600,000 600,000	166,500,000 155,400,000	56,400,000 48,600,000	0	120,300,856 127,847,060	385,650,856 368,597,060	310,024,000 279,565,000	47,839,820 52,800,579	357,863,820 332,365,579	\$743,514,676 \$700,962,639
10/13-9/14	25,950,000	1,200,000	600,000	109,050,000	32,400,000	0	132,623,596	301,823,596	252,824,000	57,404,565	310,228,565	\$612,052,161
10/15-9/16	22,050,000	900,000	150,000	99,750,000	27,000,000	0	136,493,838	286,343,838	229,229,000	61,623,870	290,852,870	\$577,196,708
10/16-9/17	18,900,000	600,000	0	91,050,000	22,500,000	0	139,462,090	272,512,090	208,065,000	65,471,012	273,536,012	\$546,048,102
10/17-9/18	16,500,000	600,000	0	83,100,000	18,900,000	0	141,604,165	260,704,165	189,761,000	68,940,774	258,701,774	\$519,405,939
10/18-9/19	14,100,000	600,000	0	76,200,000	15,900,000	0	142,934,424	249,734,424	173,030,000	72,006,720	245,036,720	\$494,771,144
10/19-9/20	12,150,000	600,000	0	69,600,000	13,200,000	0	143,514,000	239,064,000	114,972,000	73,528,025	188,500,025	\$427,564,025
10/20-9/21	10,350,000 8,850,000	0	0	63,450,000	11,100,000	0	143,250,100 142,319,144	228,150,100	102,245,000	74,614,402	176,859,402	\$405,009,502
10/21-9/22 10/22-9/23	7,500,000	0	0	58,050,000 53,100,000	9,150,000 7,650,000	0	142,319,144	218,369,144 209,037,812	90,519,000 80,366,000	75,236,640 75,441,340	165,755,640 155,807,340	\$384,124,784 \$364,845,152
10/23-9/24	6,300,000	0	0	48,600,000	6,300,000	0	138,623,963	199,823,963	71,214,000	75,231,387	146,445,387	\$346,269,350
10/24-9/25	5,850,000	0	Ö	44,400,000	5,400,000	0	135,920,535	191,570,535	63,206,000	74,640,972	137,846,972	\$329,417,507
10/25-9/26	5,100,000	0	0	40,650,000	4,500,000	0	132,783,565	183,033,565	56,056,000	73,671,696	129,727,696	\$312,761,261
10/26-9/27	4,500,000	0	0	36,900,000	3,900,000	0	129,215,670	174,515,670	49,621,000	72,378,009	121,999,009	\$296,514,679
10/27-9/28	3,900,000	0	0	33,900,000	3,000,000	0	125,285,230	166,085,230	44,044,000	70,780,996	114,824,996	\$280,910,226
10/28-9/29	3,300,000	0	0	30,900,000	2,550,000	0	121,084,480	157,834,480	39,039,000	68,924,515	107,963,515	\$265,797,995
10/29-9/30 10/30-9/31	2,850,000 2,400,000	0	0	28,200,000 25,950,000	2,250,000	0	116,662,548 111,987,696	149,962,548 142,137,696	34,749,000 30,745,000	66,845,695 64,564,164	101,594,695 95,309,164	\$251,557,243 \$237,446,860
10/30-9/31	2,400,000	0	0	25,950,000	1,800,000 1,650,000	0	104,474,742	106,124,742	27,313,000	62,097,755	89,410,755	\$195,535,497
10/32-9/33	0	Ü	0	0	1,200,000	U	97,039,720	98,239,720	24,167,000	59,482,470	83,649,470	\$181,889,190
10/33-9/34					,,		89,537,386	89,537,386	22,022,000	56,774,340	78,796,340	\$168,333,726
10/34-9/35							82,256,496	82,256,496	19,734,000	53,999,099	73,733,099	\$155,989,595
10/35-9/36							75,213,933	75,213,933	17,446,000	51,189,768	68,635,768	\$143,849,701
10/36-9/37							68,409,435	68,409,435	15,301,000	48,378,000	63,679,000	\$132,088,435
10/37-9/38 10/38-9/39							61,980,315 55,826,280	61,980,315 55,826,280	13,728,000 12,155,000	45,588,128 42,888,970	59,316,128 55,043,970	\$121,296,443 \$110,870,250
10/36-9/39							50,026,009	50,026,009	10,725,000	42,000,970	51,035,775	\$101,061,784
10/40-9/41							44,663,520	44,663,520	9,581,000	37,825,725	47,406,725	\$92,070,245
10/41-9/42							39,709,425	39,709,425	8,437,000	35,435,735	43,872,735	\$83,582,160
10/42-9/43							35,109,342	35,109,342	7,579,000	33,220,332	40,799,332	\$75,908,674
10/43-9/44							30,852,050	30,852,050	6,578,000	31,080,912	37,658,912	\$68,510,962
10/44-9/45							26,983,600	26,983,600	6,006,000	29,090,172	35,096,172	\$62,079,772
10/45-9/46 10/46-9/47							23,472,950 20,267,448	23,472,950 20,267,448	5,291,000 4,576,000	27,213,840 25,498,809	32,504,840 30,074,809	\$55,977,790 \$50,342,257
10/47-9/48							17,379,068	17,379,068	4,004,000	23,897,982	27,901,982	\$45,281,050
10/48-9/49							14,811,360	14,811,360	0	21,902,562	21,902,562	\$36,713,922
10/49-9/50							12,560,128	12,560,128	0	20,012,032	20,012,032	\$32,572,160
10/50-9/51							10,505,313	10,505,313	0	18,271,071	18,271,071	\$28,776,384
10/51-9/52							8,710,066	8,710,066	0	16,600,626	16,600,626	\$25,310,692
10/52-9/53							7,129,009	7,129,009	0	15,082,848	15,082,848	\$22,211,857
10/53-9/54 10/54-9/55							5,822,407 4,595,990	5,822,407 4,595,990	0	13,668,565 12,344,216	13,668,565 12,344,216	\$19,490,972 \$16,940,206
10/54-9/55							4,595,990 3,619,018	4,595,990 3,619,018	U	12,344,216	11,088,800	\$16,940,206
10/56-9/57							2,803,355	2,803,355		9,932,130	9,932,130	\$12,735,485
10/57-9/58							2,189,572	2,189,572		8,846,174	8,846,174	\$11,035,746
10/58-9/59							1,492,029	1,492,029		7,858,165	7,858,165	\$9,350,194
10/59-9/60							1,054,368	1,054,368		6,929,703	6,929,703	\$7,984,071
TOTAL	\$991,392,344	\$344,800,426	\$18,650,000	\$3,616,481,889	\$1,307,072,269	\$0	\$4,155,235,738	\$10,433,632,666	\$5,543,618,118	\$2,301,423,242	\$7,845,041,360	\$18,278,674,026

Note that benefits paid for RECA claims includes the amounts paid on behalf of the DOJ from the last column of Exhibit 3 Page 3 Table 8. RECA includes EEOIC payments on otherwise non-covered diseases.

The first eight rows are actual payments from Exhibit 3 Page 3 Table 8. The row for fiscal year 10/08-9/09 is estimated based on 3 quarters of actual data and an estimate for the third quarter 2009. The estimate of the amount paid in fiscal year 10/08-9/09 is not included in the estimate of future liability as of 9/2009. The remaining rows are the estimated number of claims paid from Exhibit 5 Table 2 times the amount of the benefit based on the disease. For medical, the benefit amount by year is from Exhibit 1 Page 2 Table 5.

Assumption Sensitivity Analysis

This exhibit is used to show the impact of varying some of the major assumptions used in the analysis.

This exhibit is used to show the impact of varying some of the major assumptions used in the analysis.											
	_	Undis	counted Future Liab	ility	Disc	ounted Future Liabi	lity	In Total Discounted Future Liability			
	_	Part B	Part E	Total	Part B	Part E	Total				
Current Assumptions		\$6,681,514,227	\$6,077,121,631	\$12,758,635,858	\$4,208,726,174	\$3,854,836,876	\$8,063,563,050				
Number of Claims Filed Current RECA BD CS CN - SEC CN - NONSEC BS PART E	Selected slope of fitted (-0.0375 -0.0892 -0.0404 -0.0225 -0.0450 -0.0414 -0.0300	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%			
More claims RECA BD CS CN - SEC CN - NONSEC BS PART E	Add .01 to slope -0.0275 -0.0792 -0.0304 -0.0125 -0.0350 -0.0314 -0.0200	10,712,379,473	10,220,237,782	20,932,617,255	6,220,823,931	5,589,947,603	11,810,771,533	46.5%			
Fewer claims RECA BD CS CN - SEC CN - NONSEC BS PART E	Subtract .01 from slope -0.0475 -0.0992 -0.0504 -0.0325 -0.0550 -0.0514 -0.0400	4,706,078,888	4,298,823,153	9,004,902,041	3,149,279,846	2,989,657,514	6,138,937,360	-23.9%			
Medical Inflation Rate Current	6% 8% 4%	6,681,514,227 8,046,027,764 5,759,959,141	6,077,121,631 7,128,318,874 5,423,843,958	12,758,635,858 15,174,346,638 11,183,803,099	4,208,726,174 4,724,670,575 3,832,846,368	3,854,836,876 4,185,668,787 3,626,879,750	8,063,563,050 8,910,339,362 7,459,726,118	0.0% 10.5% -7.5%			
Medical Cost Per Case Current - Part B Part E	B and E \$9,540 \$3,800	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%			
10% Higher Part B Part E	\$10,494 \$4,180	7,064,397,218	6,304,009,106	13,368,406,324	4,411,455,795	3,959,613,504	8,371,069,300	3.8%			
10% Lower Part B Part E	\$8,586 \$3,420	6,298,626,948	5,850,275,843	12,148,902,791	4,005,993,244	3,750,078,550	7,756,071,794	-3.8%			
Approval Rates RECA BD CS CN - SEC CN - NONSEC BS PART E	Current 95% 53% 18% 77% 26% 57% 44%	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%			
RECA BD CS CN - SEC CN - NONSEC BS PART E	10% Higher 100% 58% 20% 85% 29% 63% 48%	\$7,816,930,599	\$6,874,920,765	\$14,691,851,364	4,999,523,449	4,383,940,577	9,383,464,026	16.4%			
RECA BD CS CN - SEC CN - NONSEC BS PART E	10% Lower 86% 48% 16% 69% 23% 51% 40%	\$5,441,396,638	\$5,284,265,763	10,725,662,401	\$3,345,350,209	\$3,327,715,799	\$6,673,066,007	-17.2%			
Interest Rate used to D Current	4.715% 5.715% 3.715%	6,681,514,227 6,681,514,227 6,681,514,227	6,077,121,631 6,077,121,631 6,077,121,631	12,758,635,858 12,758,635,858 12,758,635,858	\$4,208,726,174 3,896,085,969 4,577,669,812	\$3,854,836,876 3,582,340,899 4,178,553,244	\$8,063,563,050 7,478,426,868 8,756,223,057	0.0% -7.3% 8.6%			